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Platinum-based chemotherapeutic drug Cisplatin represents the first line of 
defence against many tumor malignancies, including lung, ovarian and testicular 
cancers. Cisplatin exhibits its anticancer activity through the binding to DNA 
strands, inhibits transcription and triggers apoptosis. However, its efficacy is 
limited by high toxicity and incidence of drug resistance, prompting the 
development of more effective platinum-based anticancer agents. One strategy to 
overcome these limitations is to develop kinetically stable and inert platinum(IV) 
prodrugs that can resist premature aquation and binding to essential plasma 
proteins. Satraplatin is currently the most successful platinum(IV) prodrug till 
date, and is currently undergoing various clinical evaluations against cancers. The 
development of platinum(IV) prodrugs allowed a more diverse anticancer 
strategies by varying the axial ligands while keeping the platinum(II) 
pharmacophores intact. These prodrugs strategies include the use of lipophilic 
ligands, bioactive ligands, targeted drugs delivery, and photoactivation of 
platinum(IV) complexes. 
 
Classical symmetric platinum(IV) prodrug complexes are limited in their 
synthetic utility as their axial ligand sites for functionalization are identical and 
cannot fully exploit the vast potential of these prodrugs strategies. Hence, we 
developed a new class of asymmetric platinum(IV) bis-carboxylates based on the 
cisplatin template through the strategy of sequential carboxylation on a 
platinum(IV) bis-hydroxo precursor. This will allow us to access platinum(IV) 
viii 
 
complexes with different axial ligands on the same scaffolds to achieve greater 
structural and functional diversity. We applied this strategy to develop 
functionalized platinum(IV) prodrug complexes in the context of tuning their 
pharmacological properties, developing photoactivatable prodrug complexes that 
can be triggered by UV irradiation, as well as achieving ratiometric delivery of 
drug combinations. In addition, the rationale and synthetic considerations for each 
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Figure 1. Chemical structures of cisplatin and the anticancer agents used in 
combination therapy 
 
The discovery by Rosenberg that platinum complexes are capable of inhibiting 
cell division
1
 has led to the establishment of a new discipline in medicinal 
chemistry: metal-based anticancer drugs.
2 
Cisplatin, cis-
diamminediachloroplatinum (II) (Figure 1), is the first platinum-based anti-cancer 
drug that has been used to treat a series of solid tumors such as testicular cancer, 
ovarian cancer and non-small cell lung cancer.
3
 Since the introduction of cisplatin 
as a chemotherapeutic agent in combination chemotherapy, the survival rate for 
many cancer patients has increased significantly.
4
 Together with bleomycin and
                                                                                                             Chapter 1 
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etoposide, it forms the first-line chemotherapy against testicular carcinoma.
5
 It is 







 (Figure 1). 
 
       
Figure 2. Schematic diagram showing the mode of action of cisplatin upon 
administration 
 
Cisplatin enters the cell via passive diffusion and the copper transporter hCtrl 
pathway.
12 
Upon reaching the cytoplasm, cisplatin undergoes aquation and loses 
one or both of its chloride ligands due to the high concentration of aqua ligands 
present. The resulting positively charged aquatic platinum (II) species is very 
reactive and binds readily to nucleophilic purine bases in DNA to form platinated 
DNA cross-links adducts, such as 1,2-d(GpG) or 1,2-d(ApG) intrastrand cross 
links.
13, 14
  The platinated DNA adducts bend and distort the DNA double helix 





  inhibit transcription,
17
 and lead to apoptosis or programmed cell 
death eventually (Figure 2).
18 
 
            
 
Despite the overall good success cure rate of cisplatin against certain cancers, its 
efficacy is limited by high toxicity and severe side-effects arising from premature 
aquation of the platinum(II) drugs and non-selective binding towards essential 
biomolecules, which lead to inactivation of the drug.
19
 These side effects include 
nephrotoxicity, neurotoxicity, nausea and vomiting.
20
  In addition, certain cancers 
develop resistance, either inherent or acquired during prolonged treatments, 
towards cisplatin chemotherapy.
21
 This reduces the effectiveness of cisplatin, 
prompting for higher drug dosage for cancer patients.
22
 Since the discovery of 
cisplatin, thousands of platinum complexes have been synthesized and their 
biological properties studied to screen for potential anticancer agents. However, 





from cisplatin, only two other platinum complexes, carboplatin and oxaliplatin, 
have attained FDA approval as platinum-based therapeutic agents (Figure 3). 
 
     
Figure 3. Chemical structures of FDA-approved platinum(II) anticancer agents 
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The toxicity of platinum-based drugs is dependent on the rate of hydrolysis of 
leaving groups as platinum complexes with labile leaving groups are more 
reactive and react indiscriminately with biological nucleophiles other than the 
putative DNA target.
25
 Carboplatin displays higher stability and lower toxicity 
than cisplatin due to the presence of a stable chelating 1,1-
cycolubutanedicarboxylato ligand as its leaving group. Due to its lower reactivity 
and toxicity profile, carboplatin can be administered in much higher dosage than 
cisplatin (400 mg/m
2




 While carboplatin does not cause 
nephrotoxicity, its clinical use is limited by myelosuppression.
24
 Carboplatin 
exhibits the same spectrum of activity as cisplatin as they yield the same 
[Pt(NH3)2(H2O)2] pharmacophore upon hydrolysis and therefore, results in the 
formation of the same platinated-DNA adducts.
27, 28
 The second cisplatin 
anologue is oxaliplatin, the first FDA-approved platinum-based drug capable of 
overcoming tumors resistant to cisplatin and carboplatin, such as colorectal 
cancer.
29
 In oxaliplatin, the bis-ammine ligands were replaced with a single 
bidentate 1,2-diaminocyclohexane (DACH) ligand.
21
 Bearing a different 
pharmacophore from cisplatin, oxaliplatin overcome cisplatin resistance and 





The ultimate intracellular target of cisplatin and its analogues is the DNA. After 
administration, the platinum drugs are prone to interactions with many reactive 
species, particularly sulfur containing molecules.
32
 The species that compete with 
                                                                                                             Chapter 1 
5 
 
DNA for the platinum complexes include protecting agents such as thiourea and 
glutathione, cell membrane ligands, peptides and proteins such as metallothionein, 
results in low yield of platinated-DNA adducts formed.
33
 These limitations of 
cisplatin and its analogues lead to renewed interest in developing stable 





1.1 Platinum(IV) Bis-Carboxylates as Anticancer Prodrugs 
 
Platinum(IV) complex is a six-coordinate metal complex with octahedral d
6
 metal 
configurations. Unlike platinum(II), platinum(IV) complexes consist of two 
additional axial ligands that allow the fine tuning of the properties and the 
attachment of functional or targeting groups, increasing the overall functionalities 
of the complex. They obey the 18 electrons rule and can undergo reduction to 
platinum(II) species that are four-coordinated square planar d
8
 metal 
configuration complexes with the concomitant dissociation of the two axial 
ligands (Scheme 1).
34
 To exert their anticancer properties, the platinum(IV) 
complexes need to undergo intracellular reduction to platinum(II) analogues 
before they are able to bind to genomic DNA.
35, 36
 This allows the prodrugs to 
remain inert and avoid undesirable side reactions. While the mechanism of action 
is similar to their platinum(II) precursors, platinum(IV) complexes are able to 
provide greater advantages, such as oral administration, reduced side effects and 
improved efficacy. 
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Scheme 1. Chemical structure of platinum(IV) complex and its reduction to 
platinum(II) complex 
 
The ligands in the axial positions of platinum(IV) motifs allow wide range of 
structural variations that can affect the reduction potential (Ep), lipophilicity, 
reactivity and cytotoxicity (IC50) of the prodrugs. Generally, platinum(IV) 
complexes that reduce too slowly will result in low activity profiles against cancer 
cell lines as the compounds remain in their inert platinum(IV) forms and pass 
through the body without exerting anticancer activity. On the other hand, 
platinum(IV) complexes that reduce readily will result in unfavorable side effects 
associated with platinum(II) species. Studies have shown that reduction of 
platinum(IV) complexes occurs most readily when the axial ligand is chloride and 
least readily when it is hydroxide, while platinum(IV) complexes with 
carboxylate ligands in the axial positions are found to have more favorable 
reduction rates under physiological conditions (Figure 4).
37, 38, 39, 40
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Figure 4. Chemical structure of platinum(IV) complexes with differing axial 
ligands and their properties 
 
This result coincides with some of the clinical observations of platinum(IV) 
complexes that have entered clinical trials, i.e. tetraplatin, satraplatin and ipoplatin 
(Figure 5). Tetraplatin, bearing bis-chloro ligands in the axial positions, is too 
toxic as it reduces readily in the bloodstream, leading to various side effects such 
as neurotoxicity and myelosuppression.
24
 Iproplatin, bearing bis-hydroxo ligands 
in the axial positions, is found to be ineffective in the treatment of many tumor 
types and less efficacy than cisplatin and carboplatin in tumors it is active in.
24, 41, 
42, 43, 44
 Satraplatin, bearing bis-acetate ligands in the axial positions, exhibits Ep 
between that of tetraplatin and ipoplatin. It is the most successful platinum(IV) 
drug to date as it is orally active, kinetically inert and exhibits anticancer activity 
against human carcinomas that are resistance to cisplatin.
45, 46, 47
 Satraplatin is 
currently undergoing phase III clinical trial for the treatment of hormone 
refractory prostate cancer (HRPC) in combination with prednisone,
48
 and a series 
of phase I/II/III clinical trials in conjunction with various drugs against prostate 
cancer and advanced solid tumors.
24
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Spurred by the positive evaluation of satraplatin in clinical trials, there is renewed 
interest in developing platinum(IV) anticancer agents, especially those with bis-
carboxylate axial ligands. Other than the symmetric platinum(IV) complexes 
bearing identical axial ligands, asymmetric platinum(IV) complexes bearing 
different axial ligands have also been deployed and their prodrug strategies will 
be discussed in greater details in the ensuing sections. 
                         
Figure 5. Chemical structure of clinically investigated platinum(IV) complexes 
 
1.2 Synthesis of Platinum(IV) Complexes 
 
1.2.1 Classical Oxidation of Platinum(II) to Platinum(IV) complexes 
 
The most common synthetic route to the synthesis of platinum(IV) complexes 
involve a two-electron oxidation of its platinum(II) precursors using chlorine 
gas
49, 50
 or hydrogen peroxide
51
 in aqueous condition. This leads to the formation 
of platinum(IV) complexes bearing trans-chloro or trans-hydroxo ligands in the 
axial position (Scheme 2), the latter an important precursor for derivatized 
platinum(IV) complexes.
52
 In the presence of chloride ligands, such as hydrogen 
chloride, displacement of the hydroxide ligands can take place to form the tetra-
chloro platinum(IV) complex (Scheme 2).
53
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Scheme 2. Classical oxidation of bis-ammine platinum(II) complexes 
 
1.2.2 Non-Classical Oxidation of Platinum(II) to Platinum(IV) 
complexes 
 
The use of hydrogen peroxide in coordinating solvents results in asymmetric 





 the oxidation yields asymmetrical trans-alkoxo-hydroxo 
platinum(IV) complexes. When hydrogen peroxide is reacted with platinum(II) 
complexes in the presence of carboxylic acid, such as acetic or ethanoic acid,
58, 59
 
asymmetrical trans-carboxylato-hydroxo platinum(IV) complexes are obtained. 
However, this methodology does not apply to carboxylic acids with low pKa, 
such as formic
60
 and bromoacetic acid,
59
 as the stronger carboxylic acid is capable 
of protonating the second hydroxo ligand to form trans bis-carboxylate 
platinum(IV) complexes.
52
 Other non-classical methods of oxidizing bis-ammine 
platinum(II) to platinum(IV) complexes include the use of PhI(OAc)2 as an 
oxidant in dichloromethane to obtain a trans-chloro-acetato platinum(IV) 
complex,
61
 and nitrogen dioxide gas as an oxidant in aqueous potassium chloride 
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solution to yield trans-chloro-nitrito platinum(IV) complex (Scheme 3).
62
 While 
these methods provide novel synthetic pathways to access platinum(IV) 
complexes from platinum(II) precursors, they leave little rooms for structural 
variations of the scaffolds. A recently developed methodology that makes use of 
N-chlorosuccinimide in the presence of carboxylic acids or ethane-1,2-diol to 
synthesize trans-chloro-carboxylato or trans-chloro-alkoxo asymmetric 
platinum(IV) complexes via oxidative chlorination can overcome this (Scheme 3 
last).
63
 The synthesized trans-chloro-alkoxo platinum(IV) complex has a free 
alcohol group that allows further derivation of the structure by reacting with 
acids, amines, or amino acids. However, the other chloro ligand in the axial 
position remains non-functionalizable and limits further structural maneuver. 
      
Scheme 3. Non-classical oxidation of bis-am(m)ine platinum(II) complexes 
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1.2.3 Classical Synthesis of Symmetric Bis-Ammine Platinum(IV) 
Complexes 
 
Most of the synthesis of platinum(IV) complexes initiate from platinum(IV) bis-
hydroxo complex precursor, cis,cis,trans-Pt(Am)2(X)2(OH)2. The coordinated 
hydroxo ligand acts as nucleophile to ‘attack’ electrophilic agents such as acid 
anhydrides, acid chlorides, isocyanates and pyrocarbonates to yield platinum(IV) 
carboxylate, carbamate or carbonate products (Scheme 4a).
37, 64, 65, 66, 67
 The use of 
excess electrophiles in these reactions will generate the bis-symmetric 
platinum(IV) complexes. These methodologies allow structural variations in the 
platinum(IV) scaffolds that affect their chemical, physical and biological 
properties which will be discussed further in the later part of the chapter. Another 
strategy that has gained increasing popularity in recent years is the reactions of 
diacid anhydrides with platinum(IV) bis-hydroxo complex (Scheme 4b).
68, 69
 The 
resulting platinum(IV) complexes formed have two terminal uncoordinated 
carboxylic acid groups that could couple readily with molecules with amine or 
alcohol functional groups.
70
 This allows the attachment of small molecules to tune 
the lipophilicity and cytotoxic potency via structural variations,
71
 or the 
attachment of bioactive ligands for co-administrations of drugs.
72, 73
 Other than 
exploiting terminal carboxylic acid groups for conjugations, two new conjugation 





 functional groups in the axial positions of platinum(IV) complexes that 
allow facile conjugations with short chain peptide or polymeric nanoparticle 
respectively. The carbonyl groups react readily with hydrazines and 
hydroxylamines to form stable hydrazones and oximes. The second method 
                                                                                                             Chapter 1 
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attaches terminal maleimide functional groups in the axial positions of 
platinum(IV) complex.
76
 Being thiol-selective, it is used as a precursor to bind 
thiol-containing tumor-targeting molecules such as human serum albumin. 
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Scheme 4. Synthesis of bis-ammine platinum(IV) complexes 




1.2.4 Non-Classical Synthesis of Asymmetric Bis-Ammine 
Platinum(IV) Complexes 
 
The synthesis of asymmetrical platinum(IV) complexes requires sequential steps, 
a departure from classical one pot reaction designed to generate symmetrical 
platinum(IV) complexes. It is reported when trans-dichloro(1R,2R-dach)oxalato-
platinum(IV) is treated with stoichiometric amount of silver carboxylate, it will 
undergo ligand substitution with an axial chloro ligand to generate trans-chloro-
carboxylato platinum(IV) complex (Scheme 4c).
77
 Another method involves the 
use of acid anhydride to generate mono trans-carboxylato-hydroxo platinum(IV) 
complex as acid chlorides are too reactive and favor the formation of trans bis-
carboxylato platinum(IV) complexes. Excessive washing with water is required to 
quench the reaction and remove unwanted side-products when acid chlorides are 
used, decreasing the yield of mono-carboxylato platinum(IV) complex.
65, 78
 To 
obtain the mono-carboxylato platinum(IV) complex in greater yield, the reaction 
needs to be carried out in dilute polar solvent conditions such as DMSO solvent.
79
 
The mono-carboxylato platinum(IV) complex can also be synthesized via direct 
oxidation of bis-ammine platinum(II) complex precursors with carboxylic acid 
(Scheme 3).
58, 59
 Another method to selectively synthesize mono-carboxylato 
platinum(IV) complex can be achieved by using bulky N,N-dimethyl-ethane-1,2-
diamine ligand on one end of the equatorial position (Scheme 5).
80
 This allows the 
formation of only the mono-carboxylated product despite using excess succinic 
anhydride. While the free carboxylic group can be utilized for subsequent 
esterification, the unreacted hydroxo axial ligand is unable to undergo further 









Scheme 5. Selective carboxylation of bis-am(m)ine platinum(IV) complex 
 
The mono-carboxylato platinum(IV) complexes are generally used as precursor to 
generate asymmetric bis-carboxylato platinum(IV) complexes through reactions 
with acid anhydrides or carboxylic acids (Scheme 4d).
59, 79
 Asymmetric trans-
alkoxo-carboxylato platinum(IV) complexes can also be synthesized from mono-
alkoxo platinum(IV) complex using this strategy.
55, 57
 In addition, the second 
carboxylation step can also proceed with acid anhydrides bearing terminal 
functional groups (Scheme 4e). The reaction of mono-carboxylato platinum(IV) 
complex with diacid anhydrides produces asymmetric platinum(IV) complexes 
with an uncoordinated terminal carboxylic acid group that can couple to bioactive 
organic molecule or delivery vehicle.
55, 81, 82, 83
 Other than carboxylic acid 
function groups, asymmetric platinum(IV) complexes bearing a pendant azido or 
benzaldehyde functional groups have also been reported.
59, 84
 Hambley et al. has 
previously reported an asymmetric platinum(IV) prodrug of oxaliplatin bearing an 
pendant azide on the axial position that is able to undergo copper(I)-catalyzed 
click reaction with anthraquinone bearing an alkyne group.
59
 This is a feat our 




group has previously attempted using platinum(IV) prodrug of cisplatin bearing 
aromatic azide group with limited success and is still under on-going 
investigation. This can be due simultaneous redox reaction that occurs when CuI 
is being oxidized to Cu(II) species, leading to the reduction of platinum(IV) to 
platinum(II) or platinum(0) species. The other conjugation method is through the 
previously mentioned chemoselective oxime ligation.
74
 Through the development 
of asymmetric platinum(IV) complex bearing one benzaldehyde group, it allows 





Through various classical and non-classical synthetic methods, it allows a wide 
variety of symmetric and asymmetric bis-ammine platinum(IV) complexes to be 
synthesized, respectively. The careful design and synthesis of these platinum(IV) 
complexes are used in various anticancer prodrugs strategies which will be 
discussed further in the ensuing section. 
 
1.3 Applications of Platinum(IV) Bis-Carboxylates 
 
1.3.1 Platinum(IV) Complexes with  Lipophilic Axial Ligands 
 
Lipophilicity is one of the most important physicochemical properties for a drug’s 
success in the clinical development. It reflects the potential ability of a drug in 
aqueous forms to penetrate cell membranes that are hydrophobic in nature.
85
  
Lipophilic molecules have been shown to improve uptake cellularly by facilitating 
transport across cell membranes.
86, 87
 The increase in drugs’ uptake can lead to 




improved drugs’ efficacies and lower dosage regimen. Structural-activity 
relationship studies have shown that the chemical and physical properties, such as 
the redox potential, rate of reduction, lipophilicity, cytotoxicity, and water 
solubility can be altered by varying the axial ligands while maintaining 
platinum(II) pharmacophore in the equatorial position.
38, 39, 66, 71, 88
 Herein, the use 
of classical symmetric and non-classical asymmetric platinum(IV) complexes as a 
prodrug strategy to increase the lipophilicity and hence uptake will be discussed. 
 
1.3.1.1   Symmetric Platinum(IV) Complexes with Lipophilic Axial 
Ligands 
 
Dyson et al. has reported that the use of aromatic carboxylate ligands on the axial 
position of platinum(IV) prodrugs of cisplatin (Figure 6) can result in more than 
10-fold increase in cytotoxicity against a panel of lung, colon and breast 
carcinoma cell lines compared to cisplatin. This is due to improved lipophilicity 
of the symmetric platinum(IV) bis-carboxylates, which leads to increased drugs 
uptake and hence, increased drug accumulation in the tumor sites.
78
 Later on, 
Keppler et al. developed a series of symmetric platinum(IV) bis-carboxylates with 
different axial ligands using succinic and glutaric anhydride as carboxylation 
agents to study the relationship between lipophilicity, reduction potential, cellular 
accumulation and cytotoxicity of the prodrugs (Figure 6).
70, 71, 89, 90
 This class of 
compounds is developed using various amine and alcohol molecules to yield the 
corresponding amides or esters with the existing uncoordinated carboxylic acid 
groups on the platinum(IV) complexes. The experimental results show a positive 
correlation between lipophilicity and cytotoxicity, whereby the more lipophilic 




the complex, the more cytotoxic it is. More recently, Lippard et al reported a 
series of symmetric platinum(IV) bis-carbamates bearing alky or aryl substituents 
on the axial positions (Figure 6).
66
 The platinum(IV) bis-carbamates are found to 
exhibit higher degree of structural variations by adopting different isomeric forms 
depending on the rotational orientation of the ligand. However, the cytotoxicities 
of these complexes are only comparable to cisplatin against lung carcinoma and 
normal lung tissue cell lines. This is possibly due to higher stability of the 
complexes based on the electrochemical studies results, which prevents the 
complexes from undergoing reduction intracellularly to the active platinum(II) 
species.   
           
 
 
Figure 6. Chemical structures of symmetric platinum(IV) complexes bearing 
lipophilic axial ligands 
 
Although the strategy of increasing the lipophilicity of the platinum(IV) 
complexes is successful in increasing the uptake and potency of the prodrugs, a 
major setback is the poor solubility in water, which is essential for DNA-binding 
metal compounds with anti-tumor activity and clinical efficacy.
91
 On the other 




hand, while the use of hydrophilic acetate ligands increases water solubility, it 
greatly reduces the drug’s anti-proliferative efficacy.78, 92 In addition, 
platinum(IV) complexes bearing acetate ligands are generally more stable as they 
are non-bulky and do not induce any steric hindrance on the structure.
37
 Similarly, 
the presence of uncoordinated carboxylic group in the axial ligands can increase 
water solubility but decreasees the drugs’ potency significantly as the acidic 
proton can yield a negative charge upon dissociation and does not penetrate the 
cellular membrane easily.
68, 71, 78
 Hence, there is a need to improve on this strategy 
to ensure a balance between lipophilicity and water solubility. One solution will 
be the development of asymmetrical platinum(IV) complexes bearing different 
axial ligands. 
 




Figure 7. Chemical structures of asymmetric platinum(IV) complexes bearing 
lipophilic axial ligands  
 
Many reports have shown that the redox potential, rate of reduction, lipophilicity, 
and cytotoxicity of platinum(IV) complexes can be altered by varying the axial 





93, 94, 95, 96
 One of the early asymmetric platinum(IV) complexes was 
synthesized by Kidani et al. Using the FDA-approved platinum(II) anticancer 
drug, oxaliplatin, as the framework, the group found out that asymmetric trans-
(carboxylato)chloro(1R,2R-cyclohexanediamine)(oxalate)platinum(IV) complexes 




studies revealed the use of asymmetric platinum(IV) motifs result in an increased 
rate of  reduction using ascorbic acid  and increased gastrointestinal absorption 
leading to an increased in-vitro activity. Evidently, the use of asymmetric 
platinum(IV) complexes allows the tuning of physical, chemical and biological 
properties, more effectively than the symmetric counterparts which is a promising 
discovery towards developing platinum(IV) anticancer drugs in a rational 
approach.  
 
Subsequently, Keppler et al. reported the synthesis of a series of asymmetric 
trans-glycol-carboxylato platinum(IV) complexes (Figure 7).
57, 80
 The group did 
not manage to find a distinct trend between the lipophilicity, drug uptake and cell 
cycle arrest for these complexes, likely due to limited structural variations. 
However they observed strong differences in in-vitro activity when the polarity of 
the terminal group R was varied between methyl ester and ethylene glycol ester. 
The former resulted in higher activity against various carcinoma cell lines and 
induced apoptosis stronger.  
 




Later on, Our group Ang et al. showed it was possible to control the properties of 
platinum(IV) prodrugs using axial ligands with contrasting properties (Figure 7).
79
 
Through the simultaneous use of both hydrophilic and lipophilic ligands on the 
axial positions, we showed that various properties such as water solubility, 
lipophilicity and cytotoxicity could be controlled and tuned towards our desired 
properties (To be discussed further in Chapter 4). More recently, Hambley et al. 
developed a series of asymmetric mixed-carboxylato platinum(IV) prodrugs of 
oxaliplatin (Figure 7) through sequential acylation of the platinum(IV) 
complexes.
59
 The compounds were obtained by synthesis and isolation of mono-
carboxylato platinum(IV) complexes first through direct carboxylation of 
platinum(II) metal center
80
 or coupling reaction with bis-hydroxido platinum(IV) 
complex, before undergoing further carboxylation to give the desired products.
59
 
These axial ligands include alky chains such as methyl, methyl azide and 
succinate group; and aromatic compound such as anthraquinone.  
 
The ease of synthesizing asymmetric platinum(IV) complexes to give engineered 
properties that are of desired pharmacological standards can be pivotal in 
developing an effective platinum(IV) anticancer prodrug in the near future. 
 
1.3.2 Platinum(IV) Complexes with Bioactive Axial Ligands 
 
Incidences of platinum associated drug resistance often nullify cisplatin’s anti-
proliferative efficacy.
22
 Cancer drug resistance, the diminishing efficacy of 
specific chemotherapeutic agents towards their targets, is one of the most 




challenging obstacles in modern cancer medicine.
98, 99
 The underlying 
mechanisms upon which the resistance phenomena emerge is complex and differ 
across the spectrum of different cancer phenotypes.
100
 Yet they point towards the 
interconnectivity and complexity of the various molecular pathways in cancer 
biology, giving rise to multiple redundancies by which these aberrant cells can 
survive and proliferate.
101
 One strategy that is widely employed to combat 
chemoresistance is through combination therapy.
102
 By administering a cocktail of 
different anticancer drugs working against different targets, combination therapy 
aims to deter the development of drug resistance by defeating cellular survival 
pathways in a multi-pronged assault and overcome the defence mechanisms 
through therapeutic synergism.
103
 Since platinum(IV) complexes are kinetically 
inert to ligand substitution, the presence of the two axial ligands allow 
biocompatible  molecules to be tethered on the outer-sphere without 
compromising the functionality of platinum(II) pharmacophore.
60
 Upon 
intracellular reduction, stoichiometric equivalence of platinum(II) complex and 
bioactive ligands will be activated towards their respective targets. 
 
1.3.2.1   Symmetric Platinum(IV) Complexes with Bioactive Axial 
Ligands 
 
Ethacrynic acid (EA) is an inhibitor of glutathione S-transferase (GST) P1-1, an 
enzyme that is overexpressed in cancer cells and nullifies the efficacies of 
anticancer drugs.
104, 105
 To increase the potency of cisplatin, Dyson et al. 
synthesized ethacraplatin (Figure 8) by conjugating ethacrynic acid to cisplatin by 
acylation of cis, cis, trans-[Pt(NH3)2(Cl)2(OH)2], oxoplatin, with ethacrynic acyl 






 Upon activation, two molecules of ethacrynic acid and one molecule of 
cisplatin were released simultaneously. This strategy decreased the GST activity 
of A549 lung carcinoma synergistically and more efficacious than ethacrynic 
acids. 
 
In a similar strategy, Lippard et al. synthesized a series of symmetric 
platinum(IV) bis-estrogen carboxylates (Figure 8) by conjugating estrogen 
derivatives to functionalized platinum(IV) complexes via amide coupling.
72
 
Intracellular reduction afforded cisplain and two equivalents of the modified 
estrogen ligands. The bis-estrogen carboxylated platinum(IV) compounds were 
effective in upregulating HMGB1, a protein that shields platinated DNA adducts 
from nucleotide excision repair (NER). This improves the efficacy of cisplatin as 
the platinated DNA will be more prone to apoptosis when NER cannot proceed. 
 
Following the positive results, Lippard et al. proceeded to conjugate various 
targeting peptides to platinum(IV) complexes.
73, 106
 The driving force for tumor 
cell proliferation is angiogenesis, the process of forming blood vessels from pre-
existing ones. Hence, the ability to selectively target tumor endothelial cell offers 
an alternative route to treating cancer.
107, 108
 Integrins are α/β transmembrane 
receptors that bridges cell cytoskeleton to extracellular matrix, generating 
intracellular signals to allow cell proliferation.
109
 The αvβ3 and αvβ5 integrins that 
are usually absent in resting endothelial cells are expressed in many tumor 
malignancies and crucial for the tumor cells’ survivals. To target these receptors, 




the group conjugated the peptide motifs RGD (Arg-Gly-Asp) and NGR (Asn-Gly 
Arg) to platinum(IV) complexes via amide coupling (Figure 8).
73
 These peptides 
have high affinities with αvβ3 and αvβ5 integrins, and are used as targeting tools to 
direct the symmetric platinum(IV) prodrugs to selectively kill the angiogenic 
tumor endothelial cells. Other peptide chains such as AGR, Gly, (CRGDC)c and 
(RGDfk)c were also used.  
   
Figure 8. Symmetrical platinum (IV) complexes with therapeutic active axial 
ligands 
 
The conjugation to platinum(IV) complexes using longer chain peptides such as 
CNGRC (cyclic peptide Cys-Asn-Gly-Arg-Cys) to target aminopeptidase N 
(CD13/APN);
110
 TAT peptide (Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Pro-




 a 36-amino-acid peptide 




with four disulfide bridges, to selectively target tumor cells, have also resulted in 
more potent platinum(IV) complexes. 
 
Other than peptides, small bioactive molecules can also be conjugated. Lippard et 
al. reported the synthesis of mitaplatin (Figure 8), a symmetric platinum(IV) 
prodrug of cisplatin comprising of dichloroacetate in the axial positions.
112
 
Dichloroacetate is a pyruvate dehydrogenase kinase (PDK) inhibitor that can 
reverse the glycolytic metabolism in the mitochondria of most solid tumors, 
known as the Warburg effect. Upon intracellular reduction of mitaplatin, cisplatin 
and two equivalents of dichloroacetate are released to target the DNA and 
mitochondria respectively. By inducing mitochondrial dysfunction, the tumor 
cells are more sensitive to cisplatin. However, further studies reveal that ligands 
with strong electron withdrawing groups on the axial positions of platinum(IV) 
complexes will destabilize the compound, leading to premature hydrolysis in 
aqueous conditions.
113
 The electron-withdrawing dichloroacetate ligands will 
hence destabilize mitaplatin and be displaced with aqua molecules in aqueous 
biological conditions before reaching the tumor site. This result halted 
mitaplatin’s progress towards clinical evaluation. Nevertheless, mitaplatin has 
proved the viability of developing synergistic platinum(IV) complexes to delivery 
two complementary drugs as anticancer prodrug strategy.  
 
Subsequently, Shen et al. reported a symmetric platinum(IV) complex (VAAP) by 
conjugating valproic acid, a histone deacetylase inhibitor, to cisplatin using the 




same synthetic method to yield mitaplatin (Figure 8).
114
 VAAP was subsequently 
loaded in polyethylene glycol-polycaprolactone micelles (PEG-PCL) 
nanoparticles (NPs) as delivery vehicle. In-vitro results showed that PEG-
PCL/VAAP and the free VAAP were significantly more potent against cisplatin 
and oxoplatin. In-vivo results based on A549 lung tumor xenograft model 
revealed that PEG-PCL/VAAP and the free VAAP were able to inhibit the rate of 
tumor growth more effectively than oxoplatin, with limited side effects. 
 
Recently, Hey-Hawkins et al. covalently linked cyclooxygenase-2 (COX-2) 
inhibitor, ibuprofen, to cisplatin (Figure 8).
115
 COX-2 is an enzyme involved in 
tumorigenesis, a process where normal cells are transformed to cancer cells. The 
platinum(IV) prodrugs bearing the COX-2 inhibitor in the axial positions 
exhibited significant increase in cytotoxicity in a series of tumor cells tested and 
was able to overcome cisplatin resistance tumor cells. 
 
The tethering of bioactive ligands to the axial positions of platinum(IV) 
complexes have shown to be an effective prodrug strategy, as these complexes 
have displayed synergism with increased potency. However, it is not possible to 
vary the molecular ratio of the bioactive ligands to platinum(II) drug through the 
discussed methods as they only allowed a ratio of two bioactive molecules to one 
cisplatin molecule. To allow a ratiometric combinatorial drugs delivery, a 
different synthetic approach has to be adopted. 




1.3.2.2   Asymmetric Platinum(IV) Complexes with Bioactive Axial 
Ligands 
 
Through the development of asymmetric platinum(IV) complexes, it allows a 
step-wise sequential acylation of the axial ligands. Hence, it can allow the 
tethering of only one bioactive molecule in one of the two axial positions at a 
time. The remaining free axial position can be functionalized with simple organic 
molecule to alter its overall properties. It is also possible to covalently link 
another anticancer agent to the free axial position to further increase the 
functionalities of the prodrug in a triple drugs delivery approach, although there is 
no report on this till date. 
 
Our group Ang et al. reported an asymmetric trans-doxorubicin-benzoate 
platinum(IV) prodrug of cisplatin (Figure 9) which will release one molecule of 
doxorubicin and one molecule of cisplatin upon activation.
81
 Cisplatin and 
doxorubicin are currently combined in phase III clinical trials against endometrial 
adenocarcinoma, hence providing a compelling reason to link them together for 
combinatorial therapy. The presence of the benzoate ligand makes the compound 
more lipophilic to allow hydrophobic entrapment in carbon nanotubes (CNTs).
116
 
(To be discussed further in Chapter 6) 
 
More recently, our group successfully designed an asymmetric multi-model 
platinum(IV) prodrug of cisplatin. The axial ligands consist of a dual functions 
peptide and acetate or hydroxo ligand in the trans position (Figure 9).
84
 The 
peptides used in this work include annexin-1, WKYMVm (Trp-Lys-Tyr-Met-Val-




d-Met) and fMLFK (formyl-Met-Leu-Phe-Lys). The annexin-1 and WKYMVm 
peptides are able to target formyl peptide receptors (FPRs) to provide selectivity, 
while fMLFK peptide is non-targeting and used as control. As FPRs are 
overexpressed in certain malignant tumors, the selected peptides are aimed to 
target FPRs and simultaneously act as potent immune adjuvant to provoke an 
immune anticancer response to deliver therapeutic synergy.  The presence of an 
acetate ligand in the other axial position is found to decrease the platinum(IV)’s 
reduction rate by 77-folds when compared with hydroxo ligand. This can prevent 
premature reduction before reaching the target tumor site and decrease the drug’s 
efficacy. Against MC7-7 and MDA-MB-213 human breast cancer cell lines, the 
peptides conjugated platinum(IV) complexes exhibited comparable cytotoxicity 
with cisplatin, while the control with non-targeting fMLFK peptide resulted in 
negligible activity, validating the group’s approach of active targeting via 
tethering targeting peptides in platinum(IV)’s axial positions. 
 
 
Figure 9. Asymmetric platinum(IV) complexes with therapeutic active axial 
ligands 




1.3.3 Targeted Delivery of Platinum(IV) Complexes using Drug 
Carriers 
 
The strategy of delivering cytotoxic drugs selectively into cancerous cells has the 
potential to significantly improve the therapeutic efficacy of the carrier drugs.
117
 
Platinum-based chemotherapy often results in high toxicity and severe side-
effects. Its limitations are often caused by non-specific binding with essential 
plasma proteins and its inability to differentiate between healthy and tumor cells. 
Hence it is the ultimate aim of platinum-based treatment to be able to target 
cancerous cells selectively, while leaving healthy cells unscathed. To overcome 
this selectivity issue, the use of macromolecular drug carriers has been utilized to 
deliver platinum drugs to the target tissue.
118, 119, 120, 121, 122, 123
 The carriers can act 
as protective shells for the entrapped platinum drugs to prevent premature release 
and side reactions with essential plasma proteins. In addition, the surfaces of the 
carriers can be readily functionalized with passivating and targeting moieties. 
Furthermore, this can improve the drug accumulation in solid tumor due to better 
permeability and penetration of the carriers, and stay in the tumor sites which lack 




1.3.3.1   Targeted Delivery of Symmetric Platinum(IV) Complexes 
using Drug Carriers 
 
One of the early works of delivering platinum(IV) prodrugs in a nano-platform 
was reported by Lin et al.
120
 The group formulated nanoscale coordination 
polymers (NCPs) from TbCl3 and bis-succinato platinum(IV) prodrug of cisplatin, 
obtained through precipitation. The NCPs formed were subsequently stabilized by 




encapsulation in shells of amorphous silica when treated with 
polyvinylpyrollidone and tetraethyl orthosilicate (Scheme 6). By varying the 
thickness of the silica shell, the rate of release of platinum(IV) prodrug could be 
controlled and ascertained. With dissolution half-lives up to 9 hours, this strategy 
allowed the platinum(IV) complex to be release slowly, circulate around the body, 
and accumulate into the tumor site. αvβ3 integrins targeting peptide, c(RGDfK), 
was then grated onto the silica surface to enhance accumulation and selectivity 
against angiogenic cancers. The c(RGDfK)-NCPs shows increased potency 
against HT-29 colon carcinoma cells that overexpresses the αvβ3 integrins when 





Scheme 6. Targeted delivery of symmetric platinum(IV) complex in NCPs with 
targeting peptide 
 
In an alternate strategy with similar objective, Lippard et al. delivered cisplatin to 
prostate cancer cells by encapsulating hydrophobic bis-hexanoate platinum(IV) 
prodrug of cisplatin in pegylated poly(D,L-lactic-co-glycolic acid) (PLGA) 
nanoparticles (NPs) functionalized with prostate-specific membrane antigen 
(PSMA) targeting aptamers (Scheme 7).
125
 Kinetic studies revealed slow 
controlled release of platinum(IV) payload over 60 hours, indicating the 




feasibility of the NPs as the delivery vehicle. The aptamer-derivatized 
platinum(IV)-encapsulated in NPs was found to be 80 folds more superior than 
cisplatin against PSMA overexpressed prostate cancer cells, and 4 folds more 
superior than non-targeting platinum(IV)-encapsulated NPs. 
 
 




Carbon nanotubes (CNTs) and nanohorns (CNHs) have also been reported as drug 
delivery platforms for platinum-based drugs.
126, 127
 Their high aspect ratios 
allowed them to penetrate through the cellular membrane and release the platinum 
payloads directly at the tumor cells. One strategy is to load cisplatin or carboplatin 
within the inner cavity of CNTs and CNHs and subsequently release via diffusion. 
Due to the hydrophilicity of cisplatin and carboplatin, it is however not feasible to 
encapsulate the drugs in hydrophobic carriers as they can be displaced rapidly by 
aqua molecules before reaching the target site. To circumvent this, Ang and 
Pastorin et al. encapsulated an inert, hydrophobic and cytotoxic platinum(IV) 
prodrug of cisplatin within multi-walled CNTs (MWCNTs).
122
 The hydrophobic-
hydrophobic interactions between MWCNTs and platinum(IV) prodrug  favored 
entrapment and also prevented release of the prodrug in an aqueous environment. 




Upon interaction with intracellular reductants after cell penetration, the inert 
platinum(IV) prodrug was reduced to its active hydrophilic platinum(II) species, 
released from the MWCNTs, bound to DNA and eventually triggered apoptosis 
(Scheme 8).  
          
  
 
Scheme 8. Targeted delivery of symmetric platinum(IV) Complex using 
MWCNTs 
 
To study the in-vivo biodistribution, the MWCNTs encapsulating the 
platinum(IV) prodrug were functionalized with triethylene glycol (TEG) and 
delivered to female BALB/c mice.
128
 Mice treated with platinum(IV)-MWCNTs 
were found to exhibit the highest platinum content in most tissues, indicating the 
effectiveness of delivering platinum(IV) prodrugs via hydrophobic entrapment. 
The free cisplatin and cisplatin-MWCNTs did not show significant differences in 
the platinum contents, likely due to cisplatin dissolving in aqueous solution and 
gets released from the MWCNTs before reaching the tumor sites. The free 
hydrophobic platinum(IV) prodrug displayed much lower platinum content in the 
tissues due to its poor solubility in aqueous solution. This indicated that through 
drug encapsulation, the poorly soluble platinum drugs could still be delivered to 
the tumors efficiently. Interestingly, the highest platinum content was detected in 
the kidney and liver when the mice were treated with free platinum(IV) prodrug, 




while the platinum content in in the kidney tissue of the mice treated with 
platinum(IV)-MWCNTs decreased the most. These results show that delivery of 
platinum(IV) prodrug in nano-carriers can increase platinum accumulation and 
change the biodistribution profile significantly by selectively target tumor cells. 
 
In an extension of the work, Ang and Pastorin et al. attached mitochondrial-
targeting rhodamine-110 to the MWCNTs and loaded with platinum(IV) prodrug 
to yield MWCNTs-Rho-platinum(IV) to study the selectivity of MWCNTs.
129
 
Rhodamine-110 is cationic and uptakes into the mitochondria through negative 
mitochondrial membrane potential, resulting in preferential accumulation in 
cancer cells due to higher mitochondrial membrane potential in cancer cells as 
compared to normal cells. In-vitro results showed that the MWCNT-Rho-
platinum(IV) exhibited 6-fold higher potency than the free platinum(IV) complex 
when tested against A2780 cancer cells, but not in IMR90 normal cells. These 
results validated the approach of selective targeting the tumor sites via delivery 
carriers resulting in increased anti-proliferative efficacies due to better selective 
and higher drug loading profiles. 
 
1.3.3.2   Targeted Delivery of Asymmetric Platinum(IV) Complexes 
using Drug Carriers 
 
The use of asymmetric platinum(IV) prodrugs for targeted drug delivery adds a 
new dimensional approach to existing strategy by increasing the overall 
functionality of the compound. As mentioned earlier, the asymmetric 
platinum(IV) complexes can be tethered to two different molecules in the axial 




positions. In some of the examples discussed in this section, platinum(IV) 
prodrugs are tethered to nano carriers instead of being loaded directly inside them. 
 
Lippard et al. demonstrated this by conjugating asymmetric platinum(IV) 
complex, cis,cis,trans-[Pt(NH3)2Cl2(OEt)(O2CC2H4COOH)], bearing a single 
carboxylic functional group at one of its axial ligand site to single walled carbon 
nanotubes (SWCNTs) (Figure 10).
55
 The SWCNTs, functionalized with amine 
groups joined by pegylated phospholipid chains, exhibited good aqua solubility 
and low toxicity against Ntera-2 testicular carcinoma cells. Upon conjugation to 
platinum(IV) complex, the SWCNT-platinum(IV) inhibited cell viability more 
than 2-fold and 10-fold higher than the free cisplatin and platinum(IV) prodrug 
respectively. In an extension to the work, Lippard et al. replaced the ethoxide 
(OEt) group with a folate receptor targeting group, folic acid (FA), conjugated via 
a PEG-amide linker to yield asymmetric SWCNT-platinum(IV)-FA conjugate 
(Figure 10).
130
 Folate receptor (FR) is overexpressed in many tumor cells and the 
ability to target these receptors allow the platinum(IV) prodrug to be selective 
against the malignancies. As a proof of concept, the group tested SWCNT-
platinum(IV)-FA and cisplatin against FR(+) human choriocarcinoma (JAR), 
FR(+) nasopharyngeal carcinoma (KB), and a control, FR(-) testicular (Ntera-2) 
carcinoma cell lines. The SWCNT-platinum(IV)-FA was found to be only 
significantly more efficacious than cisplatin in the FR(+) cell lines. This result 
demonstrates that targeting groups on the delivery vehicles can increase the 
overall selectivity of the delivered agents. 




Other than CNTs, Lippard et al. also demonstrated the viability of delivering 
platinum(IV) complexes using polyvalent oligonucleotide gold nanoparticles 
(DNA-Au-NPs).
82
 DNA-Au-NPs are attractive drug carriers as they offer high 
cellular uptake, low toxicity and low degradability under the influence of cellular 
enzymes. Platinum(IV) mono-carboxylate, cis,cis,trans-
[Pt(NH3)2Cl2(OH)(O2CC2H4COOH)], bearing a single carboxylic group was 
conjugated to amine functionalized DNA-Au-NPs surface via amide linkage to 
yield asymmetric platinum(IV)-DNA-Au-NPs (Figure 10). The platinum(IV)-
DNA-Au-NPs displayed significantly higher activity against a series of human 
carcinoma cells than cisplatin and unconjugated platinum(IV) mono-carboxylate. 
Fluorescence microscopy studies revealed localization of the particles in the 
vesicles and cytosol after 6 and 12 hours respectively. Further staining indicated 
colocalization of the platinum(IV)-DNA-Au-NPs with the microtubules in HeLa 
cervical cancer cells. Further immuno-fluorescence studies showed the formation 
of 1,2-d(GpG) intrastrand cross-links in the nuclei of the treated HeLa cells, 
supporting the hypothesis that the platinum(IV) complex undergo intracellular 
reduction to yield active platinum(II) species, which was discharged from the 
nano carriers. 
 






Figure 10. Targeted delivery of asymmetric platinum(IV) complexes by Lippard 
et al. 
 
In another strategy, Zhang et al. conjugated symmetric bis-glutarate platinum(IV) 
prodrug of cisplatin to paclitaxcel (Ptxl) via ester coupling. Due to steric 
hindrance of Ptxl, only one molecule of Ptxl could be attached to form the 
asymmetri Platinum(IV)-Ptxl conjugate, which was subsequently loaded into 
lipid-polymer hybrid nanoparticles to yield Ptxl-platinum(IV)-NPs.
131
 Kinetic 
studies showed that up to 75% of platinum content was released from the NPs at 
pH 6.0 after 24 hours, which was likely due to hydrolysis of the ester linkage 
joining Ptxl and platinum(IV) complex. Against A2780 human ovarian 
carcinoma, the platinum(IV)-Ptxl-NPs exhibited comparable activity as cisplatin 
while the free platinum(IV)-Ptxl was ineffective. This demonstrates that the NPs 
are effective in delivering the platinum(IV)-Ptxl across the membrane diffusion 
barrier and enter the cancer cells. 
 
To overcome setbacks of non-biocompatible small molecular drugs, Jing et al. 
developed an asymmetric multifunctional platinum(IV) prodrug of cisplatin that 




consisted of mitochondria-targeting dichloroacetate (DCA) molecule on one axial 
position, and a free carboxylic group on the other end. The platinum(IV) complex 
was conjugated to a biodegradable and amphiphilic polymer, MPEGb-PCL-b-
PPL, which would assemble into nanomicelles to yield M(DCA-platinum(IV)-
polymer) (Scheme 9).
83
 Kinetic studies showed that the release of platinum from 
M(DCA-platinum(IV)-polymer) took place most readily in reducing agent such as 
ascorbic acid. Against SKOV-3 human ovarian carcinoma, M(DCA-
platinum(IV)-polymer) exhibited lower cytotoxicity than cisplatin, but 5.7 folds 
more than free DCA-platinum(IV). Cellular uptake studies showed that the 
highest platinum content was obtained in cells treated with M(DCA-
platinum(IV)-polymer), which was likely due to better internalization via 
endocytosis. 
       
Scheme 9. Targeted delivery of asymmetric platinum(IV) complex in a polymer 
that can assemble into nanomicelles 
 
Recently, Xing et al. conjugated an asymmetric photoactive platinum(IV) 
complex, trans, trans, trans-[Pt(N3)2(OH)(O2CCH2CH2CO2H)(py)2], to the 
surface of silica-coated upconversion luminescent nanoparticles (UCNPs@SiO2) 
to yield platinum(IV)-UCNPs@SiO2.
132
 Photoactivation of platinum(IV) 




complexes as a prodrug strategy has garnered considerable amount of attention in 
the late,
133 
where photo-activatable platinum(IV) prodrug complexes are reduced 
using ultraviolet (UV) light to yield cytotoxic platinum(II) species.
134, 135, 136
 
These platinum(IV) complexes possess photoactive ligands such as azido or iodo 
(To be discussed further in Chapter 5). However UV radiation has very limited 
penetration depth in biological tissues as it is readily absorbed by aromatic amino 
acids and nucleic acids in the body.
137 
Hence, this strategy allows the group to 
reduce the platinum(IV) prodrug to platinum(II) species by using UCNPs to 
absorb near-infrared (NIR) light and converting it to emissions that span a wide 
spectrum of wavelength, including UV light. Platinum content was released from 
platinum(IV)-UCNPs@SiO2 upon NIR irradiation (Scheme 10), while the free 
platinum(IV) prodrug did not undergo reduction under the same condition. MTT 
assays experiment against A2780 and A2780 cisplatin resistant human ovarian 
carcinoma showed that the platinum(IV)-UCNPs@SiO2 exhibited higher activity 
compared to cisplatin when irradiated with NIR, with up to 0.51±0.03 ng 
platinum per microgram of DNA observed in the DNA nucleus. This indicates the 
feasibility of using UCNPs as a drug carrier to overcome existing limitations of 
using UV to activate photoactivatable platinum(IV) prodrugs to enhance drug 
viability and selectivity against tumor cells. 
 




               
Scheme 10. Targeted delivery of asymmetric platinum(IV) complex in NPs using 




Chemotherapeutic drug, cisplatin remains one of the most effectively and widely 
used anticancer drugs clinically. Despite its limitations, it is able to target the 
most fundamental aspect of cancer cells, their rapidly dividing nature. To 
overcome the drawbacks of cisplatin, platinum(IV) prodrug that would undergo 
intracellular reduction to yield cisplatin offer a direct solution as it is more inert 
and stable. Classical symmetric platinum(IV) complexes offered a variety of 
prodrug strategies that include using lipophilic molecules, bioactive molecules or 
delivery carriers that would eventually release cisplatin in the tumor sites. Non-
classical asymmetric platinum(IV) complexes could also offer the same strategies 
but with more structural variations and functionalities than the classical prodrugs. 
While it is still at its infancy stage, the advantages of asymmetric platinum(IV) 
anticancer prodrugs of cisplatin over their symmetric counterparts were well 









Research Objectives and Thesis Layout 
 
The key research objective is to investigate the development asymmetric 
platinum(IV) bis-carboxylates as anticancer prodrugs that are able to overcome 
different aspects of drug resistance and improve the pharmacological properties. 
The compounds developed were based on FDA-approved cisplatin as the focal 
point, since its activities and mechanisms have been well-documented. This 
would provide a good basis for evaluation as we seek to improve its efficacy and 
mitigate its limitations simultaneously. In this dissertation, three prodrug 
strategies based on asymmetric platinum(IV) bis-carboxylates would be 
investigated. Ultimately, the compounds of interest would undergo intracellular 
reduction to yield cisplatin and exhibit similar mechanistic actions.  
 
In Chapter 3, the top-down approach of developing a novel class of asymmetric 
platinum(IV) bis-carboxylates bearing cisplatin pharmacophores through 
sequential carboxylation of oxoplatin was described. This synthetic methodology 
is a departure from classical methods used to generate only symmetric 
platinum(IV) bis-carboxylates. We were able to attach different ligands with 
contrasting properties simultaneously on the axial positions of platinum(IV) 
scaffolds, paving the way for rational development of cisplatin prodrugs.
                                                                                                             Chapter 2 
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In Chapter 4, the tunable pharmacological properties of asymmetric platinum(IV) 
bis-carboxylates were investigated. The studied compounds were compared 
against symmetric platinum(IV) bis-carboxylates in terms of lipophilicity, 
aqueous solubility, and cytotoxicity, to validate our hypothesis that the 
pharmacological properties could be tuned and engineered more effectively using 
the asymmetric scaffolds. Preliminary results identified asymmetric platinum(IV) 
bis-carboxylate 3 as a lead compound. To study structure activity relationships, 
minor structural variations of 3 in the axial positions whilst keeping the cisplatin 
pharmacophore generated a library of asymmetric platinum(IV) bis-carboxylates 
and the correlation between structural parameters and pharmacological attributes 
were analyzed. (Reprinted 2015 with permission from C. F. Chin, Q. Tian, M. I. 
Setyawati, W. Fang, E. S. Q. Tan, D. T. Leong, W. H. Ang. Tuning the activity of 
platinum(IV) anticancer complexes through asymmetric acylation, J. Med. Chem., 
2012, 55, 7571-7582 - Copyright 2012 American Chemical Society.) 
 
In Chapter 5, the photoactivatable property of platinum(IV) bis-carboxylates was 
investigated. This project depicts the use of aromatic chromophores in the axial 
positions to tune the wavelength for maximum absorption of light, λmax, instead of 
using the conventional azido or iodo ligands on the equatorial positions. This 
allowed photoreducible prodrugs of cisplatin that can be triggered by UV 
irradiation to be developed. 
 
                                                                                                             Chapter 2 
43 
 
In Chapter 6, an asymmetrical platinum(IV) prodrug of cisplatin bearing 
doxorubicin on one axial position was developed to achieve synergism in dual 
drugs delivery and overcome chemoresistance. Tuning of the lipophilic property 
of the prodrug was demonstrated using the free axial position as a handle. 
Benzoate ligand was attached on the free unconjugated axial position to improve 
lipophilicity to facilitate entrapment into tumor-targeting multi-walled carbon 
nanotubes (MWCNT). (C. F. Chin, S. Q. Yap, J. Li, G. Pastorin, W. H. Ang. 
Ratiometric delivery of cisplatin and doxorubicin using tumour-targeting carbon-
nanotubes entrapping platinum(IV) prodrugs, Chem. Sci., 2014, 5, 2265-2270 - 
Reproduced by permission of The Royal Society of Chemistry.) 
 
The dissertation is concluded with a discussion on the prospect of platinum-based 









The existing dilemna of employing platinum(IV) complexes with symmetrical 
axial bis-carboxylate ligands is too limited to fully exploit the vast potential of 
this prodrug strategy. Symmetric platinum(IV) bis-carboxylates that are lipophilic 
and cytotoxic exhibit poor aqueous solubility, and vice versa.
138
 In addition, these 
scaffolds allow limited structural variations to vary the functionalities of the 
prodrugs. Since platinum(IV) prodrugs take on the properties of their coordinating 
ligands,
139
 it should be practical to influence their properties by selectively 
“mixing-and-matching” the axial ligands. We surmise that it may be feasible to 
prepare stable asymmetric platinum(IV) bis-carboxylates that are lipophilic yet 
water-soluble, and hence more compatible with pharmaceutical applications, by 
combining carboxylate ligands with contrasting properties into the same scaffold. 
This class of asymmetric platinum(IV) carboxylate complexes will contain two 
different ligands at the axial sites which will serve as handles to fine-tune the 
pharmacological properties of the complex. Henceforth, we devised a practical 
method to carry out carboxylation onto a platinum(IV) scaffold in sequential 
steps, a departure from existing one pot procedures designed to generate 
symmetric bis-carboxylates. This synthetic strategy paves the 




way for a rational development of asymmetric platinum(IV) bis-carboxylates 
containing the [cis-Pt(NH3)2Cl2] cisplatin pharmacophore with engineered 
properties with the ultimate aim of enhancing their efficacies against cancer cells. 
  
3.2 Synthetic Strategy to Develope Asymmetric Platinum(IV) 
Bis-Carboxylates  
 
The strategy of preparing asymmetric platinum(IV) bis-carboxylates involved 
sequential carboxylation of oxoplatin at its axial ligand positions. Our approach 
was to limit the carboxylation reaction to only one hydroxyl ligand leaving 
remaining site for further systematic manipulations. The reaction was carried out 
using a less reactive carboxylating reagent and under high dilution conditions 
(Scheme 11). In previous reports, acylation using acid chlorides in concentrated 
conditions promoted the exclusive formation of symmetric platinum(IV) bis-
carboxylates.
78
 Reaction work-up also required extensive washing with water to 
remove the side-products which could dissolve water-soluble platinum(IV) mono-
carboxylates.
140, 141
 Treatment of oxoplatin with mildly reactive acid anhydrides 
or hydroxysuccinimide esters in a highly polar dilute solvent condition such as 
DMF and DMSO yielded mainly platinum(IV) mono-carboxylates. This strategy 
was also successfully applied in the mono-carboxylation of oxoplatin with 




The purified platinum(IV) mono-carboxylates were subsequently reacted with 
acid anhydrides in concentrated DMF solvent condition to synthesize asymmetric 




platinum(IV) bis-carboxylates. DMF was used as solvent instead of DMSO for 
the reactions as acetic anhydrides and other acid anhydrides can activate DMSO 
to yield DMSO-electrophile adducts that are prone to nucleophilic attacks by the 




Scheme 11. General synthetic route to prepare platinum(IV) complexes  
 
To generate the products in good yields, the mono-carboxylation of oxoplatin was 
initiated with an aryl moiety first before carboxylating the other hydroxyl group 
with an alkyl moiety. The synthesis of platinum(IV) mono-aryl carboxylates 
generated higher yield than platinum(IV) mono-alkyl carboxylates, presumably 
due to steric hindrance of the aryl groups resulting in a more favorable formation 
of the mono-aryl products. In addition, asymmetric platinum(IV) complexes 




exhibited similar solubility as aryl anhydrides since both were soluble in acetone 
and poorly soluble in diethyl ether. Purification work-up steps would require 
column chromatography if the synthetic sequence was reversed, which explained 
why our mono-carboxylation procedures always began with aromatic molecules 
first. 
 





Figure 11. Chemical structure of platinum(IV) mono-carboxylates A-I  
 
Mono-carboxylated platinum(IV) complexes A-I (Figure 11) were synthesized as 
shown in Scheme 12. Stirring oxoplatin with benzoic anhydride under high 
dilution conditions over 12 hours at room temperature generated the desired 
mono-carboxylated product A in good yields. Microwave heating at 75ºC was 
initially found to be a rapid and reproducible method for preparing A, generating 
the desired product within 1 hour. However, the low reaction yields (10%) limited 




its further applications. Mono-carboxylated platinum(IV) B-I were synthesized 
under the same high dilution conditions in DMSO with different temperature 
conditions due to different reactivities of the acid anhydrides and N-
hydroxysuccinimide esters used (Scheme 12). The symmetric bis-carboxylated 
platinum(IV) derivatives were formed as the major side-product but they were 
readily removed by acetone washing. Acetone washing also helped to remove 
unreacted reagents and the platinum(IV) mono-carboxylates were purified by 
recrystallization from DMF and diethyl ether. Like their bis-carboxylate 
congeners, mono-carboxylate platinum(IV) complexes A-I were highly soluble in 
DMF and DMSO, and insoluble in chlorinated and non-polar solvents such as 
diethyl ether and hexane. Except I, complexes A-H were soluble in water 
indicating that the hydroxyl ligand was essential for improved hydrophilic 
properties. Solubility in other polar organic solvents such as acetone and THF 
also noticeably decreased. Reaction yields constituted the major challenge to this 
synthetic approach and repeated optimizations were required to achieve moderate 
recovery.  





























Figure 12. Chemical structure of asymmetric platinum(IV) bis-carboxylates 3-22 
 
 
To generate asymmetric platinum(IV) bis-carboxylates 3-22 (Figure 12), the 
synthesized platinum(IV) mono-carboxylates were stirred with acid anhydrides in 




DMF or DCM under different reaction conditions (Scheme 13). The reactions 
were generally facile and conversion was quantitative. For example, complex A 
was converted to 3 in neat acetic anhydride at r.t. for 24 hours and reaction 
completion was indicated by complete dissolution of the reactants. Reaction 
work-up was straightforward, involving lyophilizing the reaction mixture and 
triturating the residue with diethyl ether to remove the excess and unreacted acetic 
anhydride. Complexes 4 and 5 were obtained using a similar procedure using 
DMF as a solvent and excess of glutaric and phthalic anhydride at elevated 
temperatures, respectively, in good yields.  
 
Different reaction conditions were used to activate the reactions to yield 
asymmetric platinum(IV) bis-carboxylates due to different reactivity of the acid 
anhydrides. To synthesize 6, A was stirred in propionic anhydride/DMF mixture 
at 40
o
C overnight and the completion of the reaction was indicated by the 
dissolution of the reactants. However, this was not observed when A was reacted 
with isobutyric anhydride and trimethylacetic anhydride to synthesize 7 and 8 
respectively. The reactions temperature were thus alleviated to 80
o
C and stirred 
overnight before homogeneous solutions could be obtained. This was likely due to 
the presence of more electron-donating methyl groups which decreased the 
activity of the acid anhydrides. Using this strategy, the asymmetric platinum(IV) 
bis-carboxylates could be synthesized and purified, except complexes 10, 11 and 
14. The synthesis of 10, 11 and 14 were not as facile, as undesirable side-products 
such as tetrachloro-platinum(IV) complex, Pt(NH3)2Cl4, was observed on 
1
H 




NMR and ESI/MS when the same synthetic approached was used. This could be 
due to the high reactivity and acidic nature of the haloacetate anhydrides which 
resulted in the displacement of the carboxylate ligands. The reaction solvent was 
changed to DCM instead and the reactions were able proceeded heterogeneously 
to yield the targeted compounds. Reaction work-ups include filtering the reaction 
mixture and washing the residue with excess triethyl ether to remove unreacted 
acid anhydrides. In the synthesis of complex 21, complex I was stirred with slight 
excess of benzoic anhydride in DMF at 70
o
C for 12 hours. The main challenge 
was to ascertain the conditions which would promote the consumption of I and 
removal of unreacted benzoic anhydride from the product. It was found that a 
higher temperature generated 21 in better yields and that washing the lyophilized 
reaction mixture extensively with diethyl ether could eliminate residual benzoic 
anhydride and also 21 partially, decreasing its overall yield. Nonetheless, these 












       
Scheme 13. Synthetic route to prepare asymmetric platinum(IV) bis-carboxylates 3-22 




3.5 Characterization of Synthesized Platinum(IV) Complexes 
A-I and 3-22 
 





Pt-NMR spectroscopy, and their purity were determined by elemental 
analysis or RP-HPLC. Complex A and 3 were also characterized by single crystal 
X-ray diffraction. The [M-H]
-
 parent ion of the platinum(IV) complexes were 
readily observed using ESI-MS. Fragmentation analysis resulted in the loss of 





H NMR spectra of platinum(IV) mono-carboxylates A-I, characteristic 
resonances could be observed at 5.90-6.10 ppm, which were assigned to the 
ammine ligands. After carboxylation to yield the asymmetric platinum(IV) bis-
carboxylates 3-22, these resonances were shifted downfield to 6.50-6.70 ppm 
(Figure 13). In deuterated DMSO-d6, the ammine protons of the asymmetric 
platinum(IV) bis-carboxylates 3-22 appeared as a broadened peak in the 
1
H NMR 
spectra due to coupling to quadrupolar 
14
N nuclei and hence resulted in non-
uniform charge distribution over the nuclear surface. When acetone-d6 was used 
as the solvent, well resolved ammine reasonances could be observed for the 
asymmetric platinum(IV) bis-carboxylates. However, well resolved ammine 
resonances were observed readily in platinum (IV) mono-carboxylates A-I where 
the spin–spin couplings for the ammine protons to quadrupolar 14N nuclei (1JNH = 




52–53 Hz) and 195Pt nucleus (2JHPt = 52 Hz) in 
1
H NMR spectra when deuterated 
DMSO-d6 was used, which could be due to the slow relaxation of the 
14
N nuclei.  
                           
Figure 13. Typical ammine peak in 
1
H NMR spectra of platinum(IV) (A) bis-
carboxylate and (B) mono-carboxylate in DMSO-d6 solvent 
 
195
Pt NMR resonances of the platinum(IV) complexes were measured relative to 
an external K2PtCl4 standard in D2O that resonated at -1628ppm. The 
195
Pt 
chemical shifts of A-I were observed in the region of ca. 1015–1080 ppm, while 
the chemical shifts of 3-22 were observed in a more deshielded region of ca. 
1100–1250 ppm, which could be due to the presence of an additional electron-
withdrawing ligand resulting in greater deshielding effect on the platinum(IV) 
metal center. The 
195
Pt chemical shifts of the asymmetric platinum(IV) bis-
carboxylates were consistent with the symmetric platinum(IV) bis-carboxylates 1-
2 (Figure 14) obtained directly from their corresponding anhydrides, as well as 
other reported platinum(IV) alkyl and aryl carboxylates.
140, 143, 144
  




         
Figure 14. Chemical structure of symmetric platinum(IV) bis-carboxylates 1-2 
 
Single crystals of A and 3 suitable for X-ray diffraction studies were grown 
through vapor diffusion of acetone into DMSO solution of A and diethyl ether 
into acetone solution of 1, respectively. To the best of our knowledge, complex 3 
is the first reported example of cis,cis,trans-
diamminedichlorobiscarboxylatoplatinum(IV) structure containing two different 
carboxylate ligands at the axial positions.  In the crystallographic data of A, there 
are one molecule of A and one molecule of DMSO arranged in a monoclinic 
crystal system with C2/m space group. In the crystallographic data of 3, there are 
two molecules of 1 and one molecule of acetone in a monoclinic unit cell with 
P21/c space group.  Molecular representations of A and 3 are shown in Figure 15 
and selected crystallographic structural data are given in Table 1, respectively. 
The co-ordination geometry about the platinum(IV) metal centers are octahedral. 
The average Pt-Cl and Pt-N bond lengths of 2.315(3) Å and 2.035(5) Å 
respectively are of typical values; they are held in a square-planar conformation 
similar to cisplatin. From the molecular structure of A, the Pt–Obenzoate is 2.022(4) 
Å, while Pt–Ohydroxyl is 1.975(4) Å, which is slightly shorter than Pt–Obenzoate. This 
is likely to be due to lower electron withdrawing strength of hydroxyl ligand as 




compared to the benzoate ligand, hence a shorter Pt-O bond length. From the 
molecular structure of 3, the axial O-Pt-O bond across the acetate and benzoate 
ligands is slightly bent due to the intramolecular H-bonding between the ammine 
protons and the carboxylate oxygen atoms.
140
 The Pt-Oacetate bond length of is 
2.021(5) Å which is slightly longer than Pt-Obenzoate at 2.007(5) Å but consistent 
with reported values.
140, 145
  In comparison, the average Pt-O bond length in 
symmetric platinum(IV) bis-benzoate 1 and bis-acetate 2 were reported to be 




Figure 15. Molecular representation of platinum(IV) complexes A (left) and 3 


















Pt-Ohydroxyl 1.975(4) - - - 
Pt-Oacetate - 2.01(1) - 2.007(5) 
Pt-Obenzoate 2.022(4) - 2.030(6) 2.021(5) 
Pt-N 2.044(4) 2.05(1) 2.049(6) 2.035(5) 
Pt-Cl 2.312(1) 2.30(1)  2.318(2) 2.316(2) 
C-O(Pt) 1.300(8) 1.30(2)  1.303(11) 1.301(8) 
O=C(O) 1.224(8) 1.22(2)  1.213(11) 1.230(8) 
C-C(O) 1.504(7) 1.50(2)  1.502(14) 1.496(10) 
O-Pt-O 173.3(2) 170.9(2)  176.7(3) 172.6(2) 
N-Pt-Cl 178.4(1) 179.2(4)  177.1(2) 178.0(2) 
a The bond parameters are average values between the two separate platinum(IV) molecules in the 
unit cell. 
b The bond parameters listed are average values given the symmetrical nature of the complexes. 




The development of a novel methodology to synthesize asymmetric platinum(IV) 
bis-carboxylates represents a new paradigm of platinum(IV) prodrugs strategy as 
it allows a greater structural variations that can provide greater variance in the 
pharmacological properties. This can potentially replace classical methodology of 
developing symmetric platinum(IV) bis-carboxylates and allow a more rational 
approach in platinum-based anticancer drugs design. In the ensuing chapters, the 
applications of asymmetric platinum(IV) bis-carboxylates will be explored and 
investigated. 




3.7 Experimental Procedures 
 
Unless otherwise noted, all procedures were carried out without taking 
precautions to exclude air and moisture. All solvents and chemicals were used as 
received without further treatment. K2PtCl4 was obtained from both Precious 
Metals Online and Strem Chemicals. Cisplatin, oxoplatin, 1-2 were synthesized 
and purified accordingly to literature procedures.
140, 141, 145, 146, 147 
The purities of 
asymmetric platinum(IV) precursors E-I were not performed as they were used 
subsequently in the synthesis of asymmetric platinum(IV) complexes. All other 







Pt NMR spectra were recorded on a Bruker ACF 300 
and Bruker AMX 500 spectrometer and the chemical shifts () were internally 
referenced by the residual solvent signals relative to tetramethylsilane for 
1
H and 
externally referenced using K2PtCl4 for 
195
Pt. Mass spectra were measured using a 
Finnigan MAT LCQ or Bruker Ultimate 3000 ion trap ESI mass spectrometer. 
Elemental analyses of selected platinum compounds were carried out on the 
Perkin-Elmer PE 2400 elemental analyzer by CMMAC, NUS. 
 
X-ray Diffraction Studies. X-ray data were collected with a Bruker AXS 
SMART APEX diffractometer using Mo-Kα radiation at 223(2) K with the 
SMART suite of Programs.
148
 Data were processed and corrected for Lorentz and 
polarization effects using SAINT software,
149
 and for absorption effects using the 






 Structural solution and refinement were then carried out 
using the SHELXTL suite of programs.
151
 The structure was solved by Direct 
Methods. Non-hydrogen atoms were located using difference maps and were 
given anisotropic displacement parameters in the final refinement. All H atoms 
were put at calculated positions using the riding model. 
 
Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2C6H5)OH] (A). Benzoic anhydride 
(100 mg, 440 µmol) was added to cis,cis,trans-[Pt(NH3)2Cl2(OH)2] (100 mg, 300 
µmol) in DMSO (20 mL). The reaction was stirred at r.t. for 12 h and filtered to 
remove unreacted starting materials. The filtrate was lyophilized and washed with 
acetone (3 x 10 mL) and cold DMF (1 x 5 mL), and dried in vacuo to yield the 
product as a white precipitate. Single crystals suitable for x-ray diffraction were 
grown from vapor diffusion of acetone into a solution of A in DMSO. Yield: 99 
mg (75%).The purity of platinum(IV) compounds were conducted using 
analytical HPLC on a Shimadzu Prominence using a Shimpack VP-ODS C18 (5 
µM, 120 Å, 250 x 4.60 mm i.d) column; 1.0 ml/min flow rate; 254 nm and 280 
nm UV detection.  The gradient eluent condition is as followed: 20% - 80% 
aqueous NH4OAC buffer (10 mM, pH 3.8) (solvent A) and MeCN (solvent B) 
over 20 minutes, followed by constant of of 80% of solvent B for a further 5 
minutes. 
1
H NMR (300 MHz, DMSO-d6):  7.88 (d, 2 H, Ar-H), 7.47 (t, 1 H, Ar-
H), 7.39 (t, 2 H, Ar-H), 6.06 (m, 6 H, NH3, 
1
JHN = 52.2 Hz, 
2
JHPt = 52.9 Hz). 
195
Pt 
NMR (107.6 MHz, DMSO-d6): 1022.2 ppm. ESI-MS (neg. ion mode): m/z = 
436.9 [M-H]
-
. Purity (HPLC): 94.1% at 254 nm and 93.4% at 280 nm 




respectively; retention time (tr) = 6.9 min. Anal. Calcd. for A·1.25(DMF), 
C7H12Cl2N2O3Pt: C, 24.35; H, 4.19; N, 8.59. Found: C, 24.71; H, 4.00; N, 8.60. 
 
Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2C6H4OCH3)OH] (B). The 
compound B was prepared in accordance with the method used for A using 30 mg 
of 4-methoxy-benzoic anhydride. The reaction was stirred at 50
o
C overnight. 
Yield: 13 mg (30%). 
1
H NMR (500 MHz, DMSO-d6):  7.83 (d, 2 H, Ar-H), 6.93 
(d, 2 H, Ar-H), 6.05 (m, 6 H, NH3, 
1
JHN = 51.1 Hz, 
2
JHPt = 52.4 Hz), 3.80 (s, 3 H, 
Ar-OCH3) ppm. 
195
Pt NMR (107.6 MHz, DMSO-d6): 1025.4 ppm. ESI-MS (neg. 
ion mode): m/z = 466.9 [M-H]
-
. Purity (HPLC): 95.1% at 254 nm and 95.3% at 
280 nm; tr = 8.6 min. Due to low yield of the compound, elemental analysis of the 
sample was not obtained. 
 
Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2C6H4NC2H6)OH] (C). The 
compound C was prepared in accordance with the method used for A using 30 mg 
of 3-(dimethylamino)benzoic anhydride. Yield: 4 mg (9%). 
1
H NMR (500 MHz, 





JHPt = 52.3 Hz), 2.90 (s, 6 H, Ar-NCH3) ppm. 
195
Pt NMR (107.6 MHz, 
DMSO-d6): 1024.9 ppm. ESI-MS (neg. ion mode): m/z = 479.9 [M-H]
-
. Purity 
(HPLC): 95.7% at 254 nm and 95.7% at 280 nm; tr = 9.0 min. 
 
Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2C10H6COOH)OH] (D). Napthalic 
anhydride (95 mg, 480 µmol) was added to cis,cis,trans-[Pt(NH3)2Cl2(OH)2] (60 




mg, 180 µmol) in DMF (5 mL). The reaction was stirred at 80
o
C for 6 h, treated 
with deionized water (20 mL) and cooled at 4
o
C for 12 h. The reaction mixture 
was filtered through celite to remove unreacted starting material and the solvent 
removed in vacuo. The residue was extracted with water (3 x 20 mL) and the 
aqueous extract lyophilized to yield an off-white product. Yield: 38 mg (40%). 
1
H 
NMR (300 MHz, DMSO-d6):  7.85 (d, 1 H, o-Ar-H), 7.78 (d, 1 H, o-Ar-H), 7.59 
(d, 1 H, Ar-H), 7.45-7.38 (m, 3 H, Ar-H), 6.31 (m, 6 H, NH3). 
195
Pt-NMR (107.6 
MHz, DMSO-d6): 1015.8 ppm. ESI-MS (neg. ion mode): m/z = 530.9 [M-H]
-
. 
Purity (HPLC): 95.0% at 254 nm and 95.2% at 280 nm; tr = 7.5 min. 
 
Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2CH2C6H5)OH] (E). Benzeneacetic 
acid, 2, 5-dioxo-1-pyrrolidinyl ester (42 mg, 180 μmol) was added to oxoplatin 
(40 mg, 120 μmol) in DMSO (12 mL) and stirred overnight (12 h) at 50oC. The 
reaction mixture was filtered through celite. The filtrate was lyophilized, washed 
with acetone (1 x 2 mL), diethyl ether (1 x 40 mL) and water (1 x 2 mL) before 
drying in vacuo to yield the product in white precipitate. Yield: 43.8 mg (81%). 
1
H NMR (300 MHz, DMSO-d6): δ 7.20 (m, 5 H, Ar-H), 6.54 (m, 6 H, NH3), 3.52 
(s, 2 H, −COOCH2−). 
195
Pt NMR (107.6 MHz, DMSO-d6): δ 1039.7 ppm. ESI-




Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2CH2C6H4F)OH] (F). The compound 
F was prepared in accordance with the method used for E using 45 mg of 
benzeneacetic acid, 4-fluoro-, 2, 5-dioxo-1-pyrrolidinyl ester (179 μmol). Yield: 




45.1 mg (80.1%). 
1
H NMR (300 MHz, DMSO-d6): δ 7.29  (t, 2 H, Ar-H), 7.06  (t, 
2 H, Ar-H), 5.96 (m, 6 H, NH3), 3.14 (s, 2 H, −COOCH2−). 
195
Pt NMR (107.6 





Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2CH2CH2CH2C6H5)OH] (G). The 
compound G was prepared in accordance with the method used for E using 48 mg 
benzenebutanoic acid, 2, 5-dioxo-1-pyrrolidinyl ester (191 μmol). Yield: 12.6 mg 
(20.1%). 
1
H NMR (300 MHz, DMSO-d6): δ 7.22 (m, 5 H, Ar-H), 5.97 (m, 6 H, 
NH3), 2.16 (t, 2 H, −COOCH2−), 1.74 (m, 2 H, −CH2−). 
195
Pt NMR (107.6 MHz, 




Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2C6H4CN)OH] (H). The compound 
H was prepared in accordance with the method used for E using 44 mg of benzoic 
acid, 4-cyano-, 2, 5-dioxo-1-pyrrolidinyl ester (180 μmol). Yield: 50.0 mg (83.5 
%). 
1
H NMR (300 MHz, DMSO-d6): δ 8.00 (d, 2 H, Ar-H), 7.90 (d, 2 H, Ar-H), 
6.04 (m, 6 H, NH3). 
195
Pt NMR (107.6 MHz, DMSO-d6): δ 1030.8 ppm. ESI-MS 




Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2CH2CH2CH2C15H9)OH] (I). The 
compound I was prepared in accordance with the method used for E using 30 mg 
of 1-Pyrenebutyric acid N-hydroxysuccinimide ester (78μmol). Yield: 27 mg 
(59%). 
1
H NMR (300 MHz, DMSO-d6): δ 8.47 (d, 1 H, Ar-H), 8.26 (m, 2 H, Ar-




H), 8.21 (d, 2 H, Ar-H), 8.12 (d, 2 H, Ar-H), 8.02 (m, 2 H, Ar-H), 6.00 (m, 6 H, 
NH3), 2.34 (t, 2 H, CH2), 1.96 (q, 2 H, CH2) ppm. 
195
Pt NMR (107.6 MHz, 




Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2C6H5)(CO2CH3)] (3). Compound A 
(50 mg, 114 µmol) was stirred at r.t. in acetic anhydride (5 mL) for 24 h. The 
reaction mixture was lyophilized and washed with diethyl ether (2 x 5 mL) to 
yield 1 as an off-white product after drying in vacuo. Yield: 52 mg (95%). Single 
crystals suitable for x-ray diffraction were grown from vapor diffusion of diethyl 
ether into a solution of 1 in acetone. 
1
H NMR (300 MHz, acetone-d6):  7.95 (d, 2 
H, Ar-H), 7.51 (t, 1 H, Ar-H), 7.40 (t, 2 H, Ar-H), 6.57 (m, 6 H, NH3, 
1
JHN = 53.9 
Hz, 
2
JHPt = 53.3 Hz), 1.96 (s, 3 H, -COOCH3) ppm. 
195
Pt-NMR (107.6 MHz, 
acetone-d6): 1123.0 ppm. ESI-MS (neg. ion mode): m/z = 478.92 [M-H]
-
. Purity 
(HPLC): 97.3% at 254 nm and 100% at 280 nm; tr = 9.1 min. Anal. Calcd. for 3, 
C9H14Cl2N2O4Pt: C, 22.51; H, 2.94; N, 5.83. Found: C, 22.33; H, 2.95; N, 5.79.  
 
Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2C6H5)(CO2C3H6COOH)] (4) 
Compound A (38 mg, 86.7 µmol) was stirred with glutaric anhydride (12 mg, 105 
µmol ) in DMF (10 mL) at 60
o
C for 12 h. The reaction mixture was cooled to r.t. 
and added diethyl ether (40 mL) which yielded a white precipitate. The precipitate 
was collected by centrifugation and washed with diethyl ether (3 x 10 mL) and 
dichloromethane (10 mL). The product was dried in vacuo to yield a white solid. 
Yield: 13.8 mg (29%). 
1
H NMR (500 MHz, DMSO-d6):  7.88 (d, 2 H, Ar-H), 




7.52 (t, 1 H, Ar-H), 7.42 (t, 2 H, Ar-H), 6.64 (m, 6 H, NH3), 2.28 (m, 4 H, -
COOCH3), 1.70 (m, 2 H, -CH2CH2CH2-) ppm. 
195
Pt-NMR (DMSO-d6, 107.6 
MHz): 1195.7 ppm. ESI-MS (neg. ion mode): m/z = 550.9 [M-H]
-
. Purity 
(HPLC): 95.4% at 254 nm and 95.9% at 280 nm; tr = 9.7 min. 
 
Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2C6H5)(CO2C6H4COOH)] (5). The 
compound was prepared in accordance with the method used for 4 using 30 mg of 
compound A as starting material. Yield: 15.7 mg (39%). 
1
H NMR (500 MHz, 
DMSO-d6):  7.91 (d, 1 H, Ar-H), 7.44- 7.54 (m, 8 H, Ar-H), 6.69 (br, 6 H, NH3) 
ppm. 
195
Pt NMR (107.6 MHz, DMSO-d6): 1175.7 ppm. ESI-MS (neg. ion mode, 
MeOH): m/z = 584.9 [M-H]
-
. Purity (HPLC): 97.1% at 254 nm and 97.7% at 280 
nm respectively; tr = 10.8 min. 
 
Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2C6H5)(CO2CH2CH3)] (6). 
Compound A (50 mg, 114 μmol) was stirred with propionic anhydride (5 mL) in 
DMF (5 mL). The reaction mixture was stirred for 5 h at 40
o
C and filtered 
through celite. The filtrate was lyophilized and washed with DCM (1 x 2 mL) and 
diethyl ether (1 x 40 mL) and dried in vacuo to yield the product as white 
precipitate. Yield: 29.9 mg (53%). 
1
H NMR (500 MHz, DMSO-d6): δ 7.88  (d, 2 
H, Ar-H), 7.51 (t, 1 H, Ar-H), 7.42 (t, 2 H, Ar-H), 6.65 (m, 6 H, NH3), 2.28 (q, 2 
H, −COOCH2−), 0.97 (t, 3 H, −CH3) ppm. 
195
Pt NMR (107.6 MHz, DMSO-d6): δ 
1210.1 ppm. ESI-MS (negative ion mode): m/z = 493.0 [M-H]
-
. Anal. Calcd. for 
6, C10H16Cl2N2O4Pt: C 24.30, H 3.26, N 5.67. Found: C 24.73, H 3.39, N 5.66. 




Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2C6H5)(CO2CH(CH3)2] (7). The 
synthesis was based on the procedure for 6 except isobutyric anhydride (5 mL) 
and reaction was heated for 5 h at 60
o
C. Yield: 30.5 mg (53%). 
1
H NMR (300 
MHz, DMSO-d6): δ 7.87 (d, 2 H, Ar-H), 7.52 (t, 1 H, Ar-H), 7.42 (t, 2 H, Ar-H), 
6.65 (m, 6 H, NH3), 1.02 (m, 7 H, −CH(CH3)2) ppm. 
195
Pt NMR (107.6 MHz, 
DMSO-d6): δ 1200.4 ppm. ESI-MS (negative ion mode): m/z = 507.1 [M-H]
-
. 
Anal. Calcd. for 7, C10H16Cl2N2O4Pt: C 25.99, H 3.57, N 5.51. Found: C 25.44, H 
3.77, N 5.85. 
 
Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2C6H5)(CO2C(CH3)3)] (8). The 
synthesis was based on the procedure for 6 except trimethylacetic anhydride (5 
mL) and reaction was heated for 5 h at 80
o
C. Yield: 24.7 mg (41%). 
1
H NMR 
(300 MHz, DMSO-d6): δ 7.88 (d, 2 H, Ar-H), 7.52 (t, 1 H, Ar-H), 7.42 (t, 2 H, 
Ar-H), 6.60 (m, 6 H, NH3), 1.08 (s, 9 H, −C(CH3)3) ppm. 
195
Pt NMR (107.6 MHz, 
DMSO-d6): δ 1189.8 ppm. ESI-MS (negative ion mode): m/z = 521.0 [M-H]
-
. 
Anal. Calcd. for 8, C12H20Cl2N2O4Pt: C 27.60, H 3.86, N 5.36. Found: C 27.60, H 
3.74, N 5.40. 
 
Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2C6H5)(CO2CH2Cl)] (9). The 
synthesis was based on the procedure for 6 except chloroacetic anhydride (40 mg, 
236 μmol) and reaction was stirred overnight at r.t. Yield: 25.6 mg (44%). 1H 
NMR (300 MHz, DMSO-d6): δ 7.88 (d, 2 H, Ar-H), 7.53 (t, 1 H, Ar-H), 7.42 (t, 2 
H, Ar-H), 6.65 (m, 6 H, NH3), 4.24 (s, 2 H, −CH2Cl) ppm. 
195
Pt NMR (107.6 




MHz, DMSO-d6): δ 1212.7 ppm. ESI-MS (negative ion mode): m/z = 513.0 [M-
H]
-
. Anal. Calcd. for 9, C9H13Cl3N2O4Pt: C 21.00, H 2.55, N 5.44. Found: C 
20.61, H 2.82, N 5.64. 
 
Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2C6H5)(CO2CHCl2)] (10). 
Compound A (50 mg, 114 μmol) was stirred with dichloroacetic anhydride (174 
μL, 571 μmol) in DCM (5 mL). The reaction mixture was stirred overnight (12 h) 
at room temperature and centrifuged. The residue was collected and washed with 
diethyl ether (3 x 15 mL) and dried in vacuo to yield the product as white 
precipitate. Yield: 48.2 mg (77%). 
1
H NMR (300 MHz, DMSO-d6): δ 7.8 (d, 2 H, 
Ar-H), 7.55 (t, 1 H, Ar-H), 7.43 (t, 2 H, Ar-H), 6.63 (m, 6 H, NH3), 6.51(s, 1 H, 
−CHCl2) ppm. 
195
Pt NMR (107.6 MHz, DMSO-d6): δ 1203.1 ppm. ESI-MS 
(negative ion mode): m/z = 546.9 [M-H]
-
Anal. Calcd. for 10, C9H12Cl4N2O4Pt: C 
19.69, H 2.20, N 5.10. Found: C 19.32, H 2.19, N 4.96.  
 
Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2C6H5)(CO2CHCl3)] (11). The 
synthesis was based on the procedure for 10 except trichloroacetic anhydride (100 
μL) was used. Yield: 47.9 mg (72%). 1H NMR (300 MHz, DMSO-d6): δ 7.89 (d, 
2 H, Ar-H), 7.52 (t, 1 H, Ar-H), 7.44 (t, 2 H, Ar-H), 6.58 (m, 6 H, NH3) ppm. 
195
Pt NMR (107.6 MHz, DMSO-d6): δ 1205.0 ppm. ESI-MS (negative ion mode): 
m/z = 580.9 [M-H]
-
. Anal. Calcd. for 11, C9H11Cl5N2O4Pt: C 18.52, H 1.90, N 
4.80. Found: C 18.25, H 1.98, N 4.84. 
      




Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2C6H5)(CO2CH2Br)] (12). The 
synthesis was based on the procedure for 6 except bromoacetic anhydride (5 mL) 
and reaction was stirred overnight at r.t. Yield: 41.6 mg (66%). 
1
H NMR (300 
MHz, DMSO-d6): δ 7.87 (d, 2 H, Ar-H), 7.53 (t, 1 H, Ar-H), 7.42 (t, 2 H, Ar-H), 
6.65 (m, 6 H, NH3), 4.08 (s, 2 H, −CH2Br) ppm. 
195
Pt NMR (107.6 MHz, DMSO-
d6): δ 1211.6 ppm. ESI-MS (negative ion mode): m/z = 558.9 [M-H]
-
. Anal. 
Calcd. for 12, C9H13BrCl2N2O4Pt: C 19.33, H 2.43, N 5.01. Found: C 19.55, H 
2.27, N 5.08. 
 
Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2C6H5)(CO2CH2I)] (13). The 
synthesis was based on the procedure for 6 except iodoacetic anhydride (2 mL) 
and reaction was heated at 40°C for 5 h. Yield: 50.6 mg (83%). 
1
H NMR (300 
MHz, DMSO-d6): δ 7.88 (d, 2 H, Ar-H), 7.53 (t, 1 H, Ar-H), 7.42 (t, 2 H, Ar-H), 
6.63 (m, 6 H, NH3), 3.82 (s, 2 H, −CH2I) ppm. 
195
Pt NMR (107.6 MHz, DMSO-
d6): δ 1211.6 ppm. ESI-MS (negative ion mode): m/z = 558.9 [M-H]
-
. Anal. 
Calcd. for 13, C9H13ICl2N2O4Pt: C 17.84, H 2.16, N 4.62. Found: C 17.39, H 
2.22, N 4.40. 
 
Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2C6H5)(CO2CHF3)] (14). The 
synthesis was based on the procedure for 10 except trifluoroacetic anhydride (100 
μL) was used. Yield: 61.0 mg (84%). 1H NMR (300 MHz, DMSO-d6): δ 7.89 (d, 
2 H, Ar-H), 7.55 (t, 1 H, Ar-H), 7.44 (t, 2 H, Ar-H), 6.69 (m, 6 H, NH3) ppm. 
195
Pt NMR (107.6 MHz, DMSO-d6): δ 1194.9 ppm. ESI-MS (negative ion mode): 




m/z = 533.0 [M-H]
-
. Anal. Calcd. for 14,  C9H11Cl2F3N2O4Pt: C 20.24; H 2.08, N 
5.24. Found: C 20.13, H 2.18, N 5.01. 
 
Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2CH2C6H5)(CO2CH3)] (15). 
Complex E (20 mg, 44.2 μmol) was stirred with acetic anhydride (2 mL) in DMF 
(4 mL). The reaction mixture was stirred for 5 h at 40
o
C and filtered through 
celite. The filtrate was lyophilized, washed with acetone (1 x 2 mL) and diethyl 
ether (1 x 40 mL) and dried in vacuo to yield the product as white precipitate. 
Yield: 16.8 mg (77%). 
1
H NMR (300 MHz, DMSO-d6): δ 7.29 (m, 5 H, Ar-H), 
6.63 (m, 6 H, NH3), 3.59 (s, 2 H, −COOCH2−), 1.92 (s, 3 H, −CH3) ppm. 
195
Pt 
NMR (107.6 MHz, DMSO-d6): δ 1224.7 ppm. ESI-MS (negative ion mode): m/z 
= 493.0 [M-H]
-
. Anal. Calcd. for 15, C10H16Cl2N2O4Pt: C 24.30; H 3.26, N 5.67. 
Found: C 24.81, H 3.43, N 5.45. 
 
Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2CH2C6H4F)(CO2CH3)] (16). The 
synthesis was based on the procedure for 15 except complex F (20 mg, 42.5 
μmol) was used. Yield: 15.1 mg (69%). 1H NMR (300 MHz, DMSO-d6): δ 7.30 
(t, 2 H, Ar-H), 7.09 (t, 2 H, Ar-H), 6.52 (m, 6 H, NH3), 3.58 (s, 2 H, −COOCH2−), 
1.91 (s, 3 H, −CH3) ppm. 
195
Pt NMR (107.6 MHz, DMSO-d6): δ 1228.0 ppm. 
ESI-MS (negative ion mode): m/z = 511.0 [M-H]
-
. Purity (HPLC): 97.1% at 254 
nm and 92.6% at 280 nm respectively; tr = 3.51 min. 
 




Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2CH2CH2CH2C6H5)(CO2CH3)] (17). 
The synthesis was based on the procedure for 15 except complex G (20 mg, 41.6 
μmol) was used. Yield: 10.5 mg (48%). 1H NMR (300 MHz, DMSO-d6): δ 7.21 
(m, 5 H, Ar-H), 6.53 (m, 6 H, NH3), 3.58 (s, 2 H, −COOCH2−), 1.91 (s, 3 H, 
−CH3) ppm. 
195
Pt NMR (107.6 MHz, DMSO-d6): δ 1221.2 ppm. ESI-MS 
(negative ion mode): m/z = 521.0 [M-H]
-
. Anal. Calcd. for 17, C12H20Cl2N2O4Pt: 
C 27.60; H 3.86, N 5.36. Found: C 27.73, H 3.74, N 5.40. 
 
Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2C6H4OCH3)(CO2CH3)] (18). The 
synthesis was based on the procedure for 15 except complex B (20 mg, 42.7 
μmol) was used. Yield: 12.9 mg (57 %). 1H NMR (300 MHz, DMSO-d6): δ 7.82 
(d, 2 H, Ar-H), 6.95 (d, 2 H, Ar-H), 6.64 (m, 6 H, NH3), 3.80 (s, 3 H, −OCH3), 
1.94 (s, 3 H, −CH3) ppm. 
195
Pt NMR (107.6 MHz, DMSO-d6): δ 1212.5 ppm. 
ESI-MS (negative ion mode): m/z = 509.1 [M-H]
-
. Purity (HPLC): 99.9% at 
254nm and 99.8% at 280nm respectively; tr = 3.38 min. 
 
Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2C6H4CN)(CO2CH3)] (19). The 
synthesis was based on the procedure for 15 except complex H (20 mg, 39.6 
μmol) was used. Yield: 11.5 mg (22 %). 1H NMR (300 MHz, DMSO-d6): δ 7.95 
(m, 5 H, Ar-H), 6.64 (m, 6 H, NH3), 1.85 (s, 3 H, −CH3) ppm. 
195
Pt NMR (107.6 
MHz, DMSO-d6): δ 1240.5 ppm. ESI-MS (negative ion mode): m/z = 504.0 [M-
H]
-
. Purity (HPLC): 98.4% at 254nm and 98.7% at 280nm respectively; tr = 3.21 
min. 




Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2CH2CH2CH2C15H9)(CO2CH3] (20). 
The synthesis was based on the procedure for 15 except complex I (70mg, 
116μmol) was used. Yield: 62 mg (83%). 1H NMR (300 MHz, DMSO-d6): δ 8.47 
(d, 1 H, Ar-H), 8.27 (m, 2 H, Ar-H), 8.22 (d, 2 H, Ar-H), 8.13 (d, 2 H, Ar-H), 
8.03 (m, 2 H, Ar-H), 6.56 (m, 6 H, NH3), 2.38 (t, 2 H, CH2), 1.97 (q, 2 H, CH2), 
1.92 (s, 3 H, CH3) ppm. 
195
Pt NMR (107.6 MHz, DMSO-d6): δ 1228.2 ppm. ESI-




Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2CH2CH2CH2C15H9)(CO2C6H5] 
(21). Compound I (57mg, 94μmol) was stirred with benzoic anhydride (23mg, 
99μmol) in DMF (5mL) at 70oC for 12 h. The reaction mixture was lyophilized 
and washed with diethyl ether (3 x 5mL) to yield 21 as a brown precipitate. Yield: 
30 mg (45%). 
1
H NMR (300 MHz, DMSO-d6): δ 8.47 (d, 1 H, Ar-H), 8.27 (m, 2 
H, Ar-H), 8.22 (d, 2 H, Ar-H), 8.16 (d, 2 H, Ar-H), 8.03 (m, 2 H, Ar-H), 7.89 (d, 
2 H, Ar-H), 7.53 (t, 1 H, Ar-H), 7.42 (t, 2 H, Ar-H), 6.69 (m, 6 H, NH3), 2.43 (t, 2 
H, CH2), 2.00 (q, 2 H, CH2) ppm. 
195
Pt NMR (107.6 MHz, DMSO-d6): δ 1212.3 




Synthesis of cis,cis,trans-[Pt(NH3)2Cl2(CO2C6H5)(CO2C2H4COOH)] (22) 
Compound A (50 mg, 114 µmol) was stirred with succinic anhydride (70 mg, 700 
µmol) in DMF (10 mL) at 50ºC for 24 h. The reaction mixture was lyophilized 
and washed with DCM (5 x 5 mL) to yield 22 as an off-white product after drying 
in vacuo. Yield: 44 mg (72%). 
1
H NMR (500 MHz, DMSO-d6):  12.00 (br, s, 1 




H, -COOH), 7.88 (d, 2 H, Ar-H), 7.51 (t, 1 H, Ar-H), 7.42 (t, 2 H, Ar-H), 6.62 (br, 
6 H, NH3), 2.53 (t, 2 H, -CH2), 2.40 (t, 2 H, -CH2) ppm. ESI-MS (-ve mode): m/z 











From a drug design perspective, the platinum(IV) scaffold provides an excellent 
platform upon which functionalities can be attached while maintaining the 
integrity of the platinum(II) pharmacophore [cis-Pt(NH3)2Cl2] associated with 
cisplatin. The development of asymmetric platinum(IV) bis-carboxylates allows 
different ligands with contrasting properties to be placed in the axial positions. In 
this chapter, the tunable pharmacological properties of asymmetric platinum(IV) 
prodrugs of cisplatin, particularly their aqueous solubility, stability and 
lipophilicity leading to viable anticancer complexes with enhanced cytotoxic 
profiles are investigated. Structure activity relationship studies have shown that 
the redox potential, rate of reduction, lipophilicity, and cytotoxicity of 
platinum(IV) prodrugs can be altered by varying the axial ligands.
93, 94, 95, 96
 For 
example, symmetric platinum(IV) prodrugs bearing hydrophobic aromatic 
carboxylate ligands exhibit more than 10-fold increase in cytotoxicity against a 
panel of lung, colon and breast carcinoma cell lines compared to cisplatin due to 
improved lipophilicity. Platinum(IV) prodrugs containing alkyl carboxylate axial 
ligands, on the other hand, are generally less efficacious.
140
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Henceforth, we postulate that asymmetric platinum(IV) prodrugs bearing both 
hydrophobic aromatic and hydrophilic alkyl carboxylate ligands on the same 
scaffolds will exhibit good lipophilicity and solubility, and ultimately enhance 
their anti-proliferative efficacies against cancer cells. 
 
4.2 Evaluating the Tunable Pharmacological Properties of 






Figure 16. Chemical structure of platinum(IV) complexes evaluated for tunable 
pharmacological properties 
 
As a proof of concept, platinum(IV) complexes A-D and 1-5 were synthesized 
(Chapter 3) and their lipophilicities, solubilities, and cytotoxicities studied to 
evaluate the tunable properties of asymmetric scaffolds. Other than cisplatin and 
oxoplatin, symmetric platinum(IV) bis-benzoates 1 and bis-acetates 2 were also 
used as controls since they consist of axial ligands with contrasting properties and 
would be expected to exhibit distinctive results in the studies, while the 
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asymmetric platinum(IV) bis-carboxylates were expected to exhibit parameters 
intermediate of 1 and 2. 
 
4.2.1 Evaluating the Tunable Lipophilicity and Aqueous Solubility of 
Asymmetric Platinum(IV) Bis-Carboxylates 
 
Lipophilicity, expressed as the logarithms of n-octanol/water partition coefficient 
LogPow, is a good estimate for the drugs’ ability to penetrate cancer cells. It 
describes the distribution of the drug between the polar water phase and non-polar 
n-octanol phases, and an important tool in predicting the transport and activity of 
the drugs.
152
 Recently, Hall and co-workers developed a method to 
computationally derive LogPow values of platinum(IV) complexes using quantum 
mechanical calculations in order to predict their whole-molecule lipophilicity and 
concluded that there is a strong correlation between lipophilicity and drug 
accumulation.
153, 154
 Notably, complexes that are too lipophilic or hydrophilic 
show little or poor bioavailability.
155
 Platinum(IV) complexes that are highly 
lipophilic will get embedded in the membrane due to favorable hydrophobic 
interaction or be too insoluble in aqueous media, an important pharmacological 
property. Platinum(IV) complexes that are highly hydrophilic will not be able to 
pass through the cell membrane and exert its activity. 
 
LogPow values of the synthesized platinum(IV) complexes were determined using 
the shake-flask method (Table 2). The concentrations of the platinum(IV) 
complexes in aqueous and n-octanol media were determined by ICP-OES. In 
addition, the tested compounds exhibited stability up to 72 hours when studied 
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with RP-HPLC, providing a good validations of the shake-flask method in 
ascertaining the lipophilicity of the platinum(IV) complexes. Besides shake-flask, 
LogPow values of other anticancer drugs had also been determined using RP-
HPLC and group-additive methods.
156
 The synthesized complexes, each 
containing at least an aromatic carboxylate axial ligand, were significantly more 
hydrophilic than symmetric platinum(IV) bis-benzoate 1 as evidenced by their 
lower LogPow values. Mono-carboxylated complexes A-D were evidently more 
hydrophilic than the bis-carboxylates, presumably due to the presence of 
uncarboxylated hydroxyl ligand. Functionalization of the benzoate ligands with 
H-bonding groups such as carboxylic group increased hydrophilicity, with D 
displaying the lowest LogPow amongst its class despite the bulkier naphthalate 
ligand. Comparing 1 with the series of asymmetric platinum(IV) bis-carboxylates 
3-5, replacement of one benzoate with a less lipophilic ligand, namely acetate, 
glutarate or phthalate, improved hydrophilicity significantly. For example, 5 
differed structurally from 1 by the addition of an ortho-carboxylic group and 
exhibited a 0.75 units reduction in LogPow. Notably, A and 3 exhibited a LogPow 
reduction of -1.6 and -1.2 unit compared to 1 and differing only in the nature of 
the one of the axial ligand. In comparison, cisplatin, oxoplatin and platinum(IV) 
bis-acetate 2 were highly hydrophilic with LogPow values determined to be -2.03, 
-2.12 and -2.00, respectively. Under normal room conditions, the solubility of A 
and 3 in water were observed to be higher than 300 µg/mL whereas 1 was 
observed to be too poorly soluble to be determined. Cisplatin and 2 both exceeded 
1 mg/mL solubility under these conditions. For a more quantitative measurement, 
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saturated solutions of A, 1 and 3 were prepared at 80°C under agitation, filtered 
and their platinum levels determined by ICP-OES. The results indicated that 
mono-carboxylate A was twice as soluble as asymmetric bis-carboxylate 3 and 
four times more soluble than symmetric bis-benzoate 1. This provided a 
validation on the proposed approach of tuning the lipophilicity of platinum(IV) 
carboxylate complexes through asymmetric ligands with contrasting attributes. 
The lipophilicity of the platinum(IV) complexes was also determined by reversed-
phase liquid chromatography where a standard curve was first obtained by 
determining the retention time of compounds with known log Poct values.
157
 
However, this method is more suitable for comparison of lipophilic compounds as 
it is only able to generate positive log Poct values. The group additive method, on 
the other hand, is generally used for organic compounds and not applicable for the 
platinum(IV) complexes studied. 
 















 A2780 A2780/Cis 
A -0.59 ± 0.12 0.79 1.22 ± 0.03 2.41 ± 0.27 7.30 ± 2.31 3.0 
B -0.50 ± 0.09 0.92 - 5.11 ± 0.61 16.97 ± 4.01 3.3 
C -0.87 ± 0.16 1.17 - 5.80 ± 0.73 20.21 ± 5.26 3.5 
D -1.14 ± 0.18 0.93 - 19.03 ± 0.91 > 50 - 
1 1.01 ± 0.01 1.19 0.27 ± 0.01 0.048 ± 0.004 0.23 ± 0.07 4.8 
2 -2.00 ± 0.18 1.34 - > 20 > 20 - 
3 -0.19 ± 0.04 1.54 0.62 ± 0.04 0.83 ± 0.14 6.24 ± 0.94 7.5 
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4 -0.46 ± 0.04 2.19 - 1.95 ± 0.30 26.41 ± 1.72 13.5 
5 0.25 ± 0.02 - - 4.95 ± 0.77 24.90 ± 1.81 5.0 
cisplatin -2.03 ± 0.47 - 3.37 ± 0.05 1.63 ± 0.17 13.91 ± 2.04 8.5 
oxoplatin -2.12 ± 0.24 - - > 50 > 50 - 
a LogPow values determined via the shake-flask method against 1:1 n-octanol:0.9% v/w NaCl 
partition. 
b LogPow values determined via RP-HPLC method. 
c IC50 values is the concentration of platinum complexes required to inhibit 50% of the cell growth 
with respect to control groups, measured by MTT assay after 72 h exposure. Data obtained are 
based on the average of at least three independent trials and the reported errors are the 
corresponding standard deviations. The IC50 were corrected using actual [Pt] determined using 
ICP-OES.  




4.2.2 Evaluating the Tunable Anti-Proliferative Properties of 
Asymmetric Platinum(IV) Bis-Carboxylates 
 
The efficacy of cisplatin and platinum(IV) prodrugs on the cell-growth inhibition 
of A2780 and A2780/Cis human ovarian carcinoma was evaluated to determine 
the cytotoxicity of the complexes (Table 2). Briefly, after the cells were adhered 
to the multiwall plate surface, they were exposed to varying concentrations of the 
platinum complexes in serum-free medium for 6 hours. The media was replaced 
with complete media and left to incubate for a further 66 hours before the viability 
of the remaining cells was determined. The data was presented as % survivial 
against non-treated controls and the concentrations required to inhibit cell 
viability by 50% (IC50) were interpolated from the graph (Figure 17). All 
experiments were carried out in triplicates and repeated. The purity of the 
compounds was established using elemental analysis and RP-HPLC and found to 
exceed 95%. To further mitigate the effects of contamination, platinum 
concentration of the platinum complex stock solutions were determined using 
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ICP-OES and the IC50 values were adjusted to actual platinum concentration 
values.  
 
The archetypal complex 1 was 30-fold more cytotoxic than cisplatin in both cell 
lines. The enhanced activity was earlier attributed to its high lipophilicity and 
increased drug uptake. On the other hand, 2, despite sharing the same [cis-
Pt(NH3)2]-pharmacophore as 1, was poorly cytotoxic despite its good aqueous 
solubility. The poor aqueous solubility of 1 undermined its usefulness as a 
potential drug that can be administered intravenously.
95, 140
 With the exception of 
mono-carboxylate D, the newly synthesized platinum(IV) complexes exhibited 
the same order of magnitude of cytotoxicity as cisplatin (Table 2). Complex A 
was the most efficacious amongst the mono-carboxylate complexes tested while 3 
was the most effective among the panel of asymmetric platinum(IV) bis-
carboxylate prepared. The IC50 values of these complexes against both cell lines 
were in the same order of magnitude range comparable to cisplatin. Notably, all 
platinum(IV) prodrug complexes exhibited cross-resistance to the cisplatin-
resistant A2780 variant (A2780/Cis) with resistance factors between 3.3 to 13.5. 
Resistance to cisplatin in A2780/Cis cells had been attributed to enhanced cellular 
repair via mismatch repair mechanisms.
158
 This was reasonable since these 
complexes are expected to exert their activity via DNA-binding after intracellular 
reduction to cisplatin, they would be affected by the same resistance mechanisms 
resulting in lower efficacies.  
 
                                                                                                             Chapter 4 
80 
 
Taken together, the data obtained suggested a direct link between lipophilicites 
and efficacies in inhibiting cancer cell viability within this class of platinum(IV) 
complexes (Table 2). Highly hydrophilic platinum(IV) complexes oxoplatin and 2 
are poorly efficacious when compared to the lipophilic mono- and bis-
platinum(IV) carboxylates. Furthermore, lipophilic platinum(IV) bis-carboxylates 
were generally more efficacious than platinum(IV) mono-carboxylates despite 
only minor structural changes. Complexes A and 3, for example, differed only by 
one axial ligand group (hydroxyl vs acetate). It was previously noted that these 
axial ligands affected reduction potential of platinum(IV) complexes, particularly 
hydroxyl ligands, which accounted in part for the poor efficacy of oxoplatin.
159
 In 
addition, asymmetric platinum(IV) complex 3 benefitted directly from higher 
lipophilicity than A. It should also be highlighted that both complex A and 3 were 
less efficacious compared to 1. Their lower efficacies may be directly due to their 
significantly lowered lipophilicities and hence poorer uptake. However, complex 
1 was not directly soluble in water, unlike A and 3, and would be problematic for 
intravenous administration and further pharmaceutical development. The poorer 
efficacy of D, ca. 12-fold less than cisplatin, could be attributed to the formation 
of charged species in the culture media upon dissociation of the acidic carboxylic 
proton which would be repelled from the hydrophobic cellular membrane 
resulting in lower cellular uptake, and could also explain the slightly higher IC50 
values for 4 and 5 compared to 3.
140
 In addition, complex 3, consisting of both 
benzoate and acetate ligands in the axial positions, exhibited IC50 between 1 and 2 
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while being comparable to cisplatin. This validated our hypothesis of tuning the 
cytotoxicities of platinum(IV) prodrugs through asymmetric acylation. 
 
 
Figure 17. Dose-dependent drug efficacy studies for cisplatin, complexes A-D, 1 
and 3-5 on A2780 and A2780/Cis tumor cells 
 
 
4.3 Evaluation of the Mechanism of Asymmetric Platinum(IV) 
Bis-Carboxylates 
 
The putative mechanism of action of inert platinum(IV) prodrugs involved their 
conversion to cytotoxic platinum(II) species via chemical reduction. Earlier 
reports suggested a strong relationship between the ease of reduction with 
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anticancer activity of these complexes. For example, platinum(IV) complexes 
with axial chloro ligands were easily reduced and exhibited high cytotoxicity 
while those with axial hydroxyl ligands were poorly cytotoxic by virtue of their 
unfavorable reduction potential.
159
 We therefore sought to establish whether these 
newly synthesized water-stable asymmetric platinum(IV) carboxylates require 
reduction to their platinum(II) congeners for activity, therefore fulfilling their role 
of prodrugs. This was corroborated in part by previous experimental evidence 
showing that 1 reacted with sodium diethyldithiocarbamate (DDTC) only after 
treatment with a bio-reductant such as ascorbic acid or glutathione to form yellow 
Pt(DDTC)2 in the same manner as cisplatin.
160
 Without reduction, platinum(IV) 
complex 1 remained unreactive towards DDTC.
122
 To establish the prodrug 
mechanism from the inert platinum(IV) carboxylates to reactive platinum(II) 
species, we investigated their ability to bind DNA, the putative biological target, 
after activation by chemical reduction. In its active platinum(II) state, cisplatin 
exerts its bioactivity by forming genomic Pt-DNA adducts that interfered with 
replication and transcription processes.
161
 The high reactivity of platinum drugs 
towards guanosine arose from the nucleophilic nature of the N7-position on the 
guanosine base and cooperative H-bonding interaction between the ammine 
ligand and exocyclic O6-position. 5’-Guanosine-2’-deoxymonophosphate (5'-
dGMP) was used as a model for DNA so that analysis could be carried out using 
RP-HPLC.  
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Treatment with cisplatin readily yielded mono-functional [Pt(NH3)2Cl(5’dGMP)] 
and bis-functional [Pt(NH3)2(5’dGMP)2] adducts, consistent with literature 
reports,
162, 163
 which could be isolated from RP-HPLC and identified using ESI-
MS. Treatment of platinum(IV) complexes oxoplatin, A, 1, and 3 with 5’dGMP 
however, did not elicit the same response and the complexes remained unreactive 
towards 5’dGMP over a period of 72 hours. However, after these complexes were 
incubated with 3 mM ascorbic acid, they reacted readily with 5’dGMP to form 
monofunctional [Pt(NH3)2Cl(5’dGMP)] and bifunctional [Pt(NH3)2(5’dGMP)2] 
adducts akin to those formed by cisplatin (Figure 18). Based on the results, we 
concluded that the platinum(IV) carboxylates were themselves inert to ligand 
substitution reactions. The RP-HPLC studies reaffirmed their aqueous stability in 
the presence of 5’dGMP after 72 hours. However, upon reduction by ascorbic 
acid, reactive platinum(II) species were formed which bind readily with 5’dGMP 
to form platinated adducts. These adducts were consistent with those formed by 
cisplatin under ambient conditions. Previous studies done by our group also 
showed that asymmetric platinum(IV) complexes bearing the cisplatin template 
were reduced to cisplatin conclusively.
84
 Taken together, these results suggested 
that the inert and stable platinum(IV) carboxylates, including the newly 
synthesized mono-carboxylates and asymmetric bis-carboxylates, functioned as 
prodrugs of cisplatin that were activated upon chemical reduction. 
 




Figure 18. HPLC chromatograms showing 5’-dGMP; reaction of complex A with 
5’-dGMP; reaction of complex A with 5’-dGMP in the presence of 3 mM 
ascorbic acid; and reaction of cisplatin with 5’-dGMP 
 
4.4 Expanding the Scope of Investigation on Asymmetric 
Platinum(IV) Bis-Carboxylates 
 
Having proved platinum(IV) prodrugs could be fine-tuned to achieve desired 
pharmacological properties using asymmetric carboxylation and successfully 
developed a lead compound 3,
79
 we expanded our scope of investigation to a 
library of asymmetric platinum(IV) bis-carboxylates. Through minor structural 
variation of the axial ligands whilst keeping the cisplatin pharmacophore intact, 
we rationally designed 3 series of asymmetric platinum(IV) bis-carboxylates 6-
19 (Figure 19) to establish how the structural parameters would affect the 
pharmacological attributes. This expanded class of asymmetric platinum(IV) 
complexes were synthesized using the strategy detailed in Chapter 3 involving 
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sequential acylation of oxoplatin to yield the platinum(IV) mono-carboxylates 




Figure 19. Chemical structure of asymmetric platinum(IV) complexes 
investigated for their structure activity relationships 
 
In series 1 (6–8), the acetate ligand was replaced with alkyl carboxylates with 
increasing steric encumbrance. In series 2 (9–14), the acetate ligand was replaced 
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with haloacetate ligands with vary electron-withdrawing properties. In series 3 
(15–19), the benzoate ligand was altered either by adding electron-
donating/withdrawing groups directly to the phenyl moiety or increasing the 
distance between the phenyl and carboxylate groups. This systematic exploration 
of their structural space was geared towards the discovery and pharmacological 
optimization of a cisplatin prodrug suitable for eventual drug development. 
 
4.4.1 Evaluating the Stability of the Expanded Asymmetric 
Platinum(IV) Bis-Carboxylates Series 
 
One of the main considerations in developing stable platinum(IV) prodrugs was to 
ensure the low spin octahedral d
6 
platinum(IV) would remain inert and get 
activated only via cellular reduction at the tumor sites to release the high spin 
square-planar d
8
 platinum(II) drugs. To determine the stability of this class of 
compounds, asymmetric platinum(IV) bis-carboxylates 6-19 were dissolved in 40 
mM of HEPES buffer at pH 7.4 for 72 hours. The stability of the complexes was 
monitored by RP-HPLC (Figure 20) and the results depicted in Table 3. The 
stability of 3 was also studied as a reference control. Other than complex 10, 11 
and 14, all asymmetric platinum(IV) bis-carboxylates exhibited good aqueous 
stability for at least 72 hours. From the RP-HPLC spectra, the intensity of the 
peaks signaling 10, 11 and 14 decreased significantly within 24 hours, which was 








Figure 20. HPLC chromatograms depicting the stability of complex 6 after 72 h 
and instability of complex 10 after 24 h 
 
Previously, it was shown that platinum(IV) prodrugs bearing strong electron 
withdrawing bis-haloacetato ligands such as dichloroacetate and trifluoroacetate 
in the axial positions were unstable.
112, 113
 We attempted to circumvent this 
limitation through mono acylation of these ligands in our asymmetric 
platinum(IV) scaffolds with limited success. The poor stability of 10, 11 and 14 
rendered them unsuitable for further studies.  
 
4.4.2 Evaluating the Reduction Rate of the Expanded Asymmetric 
Platinum(IV) Bis-Carboxylates Series 
 
The reduction rate of platinum(IV) complexes played an important role in 
determining the cytotoxicity of the prodrugs, as platinum(IV) complexes that 
reduced readily would result in unfavorable side effects associated with 
platinum(II) species, while those that reduced too slowly might pass through the 
body without exerting anticancer activity.
37, 38, 39, 40
 The reduction rate of the 
platinum (IV) complexes were studied in the presence of 30 mM ascorbic acid as 
a model of outer space reductant in 40 mM HEPES buffer and monitored at 
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regular time intervals using RP-HPLC. A significantly higher concentration of 
ascorbic acid was used to minimize experimental error due to oxidation of 
ascorbic acid by dissolved O2 and to stimulate psychological reductive 
environment. The area of the signal corresponding to each platinum(IV) complex 
in the RP-HPLC spectra were monitored and measured at regular time intervals 
upon addition of ascorbic acid. The reduction of the platinum(IV) complexes with 
respect to time were plotted in Figure 21 and the time taken for platinum(IV) 
complexes to be reduced to 50% of its initial concentration (t1/2) were tabulated in 
Table 3. Platinum(IV) mono-carboxylate A registered a t1/2 of 13 min, which was 
significantly lower than asymmetric platinum(IV) bis-carboxylate 3 (t1/2 = 124 
min). The reduction rates of all asymmetric platinum(IV) bis-carboxylates were 
significantly lower than platinum(IV) mono-carboxylate despite being endowed 
with an additional electron withdrawing carboxylate ligand. This indicated that 
the rate of reduction is dependent on the ability of the platinum(IV) complex to 
bridge with reducing agents and facilitate electron transfer resulting in reduction 




Across series 1, increased steric encumbrance and presence of more electron 
donating methyl groups reduced the rate of reductions, suggesting stabilization of 
the platinum(IV) complexes. Complexes 6-8 had t1/2 of 148, 164 and 197 min 
respectively. The presence of electron donating methyl groups would increase the 
electron density around the platinum(IV) metal center and strengthen the Pt-Oalkyl 
bond, making the compounds less susceptible to reduction. Across series 2, the 
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reduction of the platinum(IV) complexes did not proceed faster than anticipated 
when the methyl groups were replaced with electron withdrawing halogen groups. 
Instead, the reduction rate of complex 9 and 12 was comparable to 3 with t1/2 of 
129 and 128 min respectively. Complex 13 reduced the slowest in series 2, with a 
t1/2 of 209 min, presumably due to steric hindrance of bulky iodoacetate group 
that blocked ascorbic acid from accessing the platinum(IV) metal center.  
 
Across series 3, the asymmetric platinum(IV) bis-carboxylates were more stable 
towards reduction compared to 3, particularly 15-17 which were platinum(IV) 
bis-alkyl carboxylates with distal aryl groups. Complex 15 had a t1/2 of 333 min 
while 17 had t1/2 of >400 min, indicating a longer alkyl chain could nullify the 
electron withdrawing effect of the benzoate moiety and stabilize the platinum(IV) 
complex. Interestingly, Complex 16 also had a t1/2 of >400 min, indicating that the 
addition of electron-withdrawing fluoro group at the benzyl moiety in 16 did not 
significantly perturb the reduction rates of 15. This was in contrast to 
platinum(IV)-bis-aryl carboxylates 18 and 19, where the presence of electron 
donating methoxy substituent helped to stabilize 18 (t1/2 >400 min), while electron 
withdrawing cyano substituent destabilized 19 (t1/2 = 205 min). This could mean 
that increasing the bond distance between the benzoate moiety and platinum(IV) 
metal center could neutralize the electron withdrawing effect by the substituents 
on the aromatic ring. Henceforth, This result validated our approach of achieving 
fine-tuning into the intrinsic properties of asymmetric platinum(IV) bis-
carboxylates through minor structural variations of the axial ligands. 




Figure 21. Graphs depicting the reduction asymmetric platinum(IV) complexes  
 
 
Table 3. Stability and reduction rates of asymmetric platinum(IV) complexes 












A Ph (OH) > 3days  (5.3 ± ).3) x 10-2 13 
3 Ph CH3 > 3days  (5.6 ± 0.3) x 10-3 124 
6 Ph CH2(CH3) > 3days (4.7 ± 0.1) x 10-3 148 
7 Ph CH(CH3)2 > 3days (4.2 ± 0.1) x 10-3 164 
8 Ph C(CH3)3 > 3days (3.5 ± 0.0) x 10-3 197 
9 Ph CH2Cl > 3days (5.4 ± 0.0) x 10-3 129 
10 Ph CHCl2 < 1 day - - 
11 Ph CCl3 < 1 day - - 
12 Ph CH2Br > 3days (5.4 ± 0.1) x 10-3 128 
13 Ph CH2I > 3days (3.3 ± 0.1) x 10-3 209 
14 Ph CF3 < 1 day - - 
15 CH2Ph CH3 > 3days (2.1 ± 0.1) x 10-3 333 
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 a The rate equations were taken to be pseudo 1st order reaction as large excess of ascorbic acid 
were used with respect to the concentration of platinum(IV) complexes 
 
 
4.4.3 Evaluating the Lipophilicities and Aqueous Solubilities of the 
Expanded Asymmetric Platinum(IV) Bis-Carboxylates Series 
 
LogPow values of the platinum(IV) complexes were determined using the shake-
flask method, where the relative solubility of the compounds in n-octanol and 
water were measured.
165
 The platinum (IV) mono-carboxylate A was more 
hydrophilic than the asymmetric platinum(IV) bis-carboxylates with a LogPow of -
0.70 (Table 4) due to the presence of the uncarboxylated hydroxyl ligand capable 
of forming hydrogen bonds with water molecules. Complex 3 exhibited LogPow 
of -0.28, which was slightly more hydrophilic than previously measured LogPow 
of -0.19 (Table 2). This is likely to be due to difference in experimental setups 
and errors. Nonetheless, each set of experiment was repeated in triplicates to 
ensure consistency in the results. 
 
In series 1, the LogPow values of the complexes lie between -0.08 and 0.46, where 
bis-carboxylated platinum(IV) complexes become increasingly more lipophilic 
with additional methyl groups. In series 2, the LogPow values lie between 0.13 and 
0.56. Complex 13 was the most lipophilic with a LogPow of 0.56 in the series and 
this was attributed to the presence of sterically bulky iodomethyl ligand.
88
 In 
series 3, the LogPow values lie between -0.47 and 0.24. Complex 17 was the most 
16 CH2PhF CH3 > 3days (1.5 ± 0.0) x 10-3 > 400 
17 C3H6Ph CH3 > 3days (9.2 ± 0.3) x 10-4 > 400 
18 PhOMe CH3 > 3days (9.5 ± 0.4) x 10-4 > 400 
19 PhCN CH3 > 3days (3.4 ± 0.0) x 10-3 205 
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lipophilic in the series with a LogPow value of 0.24, which was attributed to the 
presence of increased alkyl chains. 
 
Among the synthesized asymmetric platinum(IV) complexes, Complex 8 and 13 
exhibited the highest lipophilicity and were due to the increased size of the overall 
complex which outweighed the effect of other factors such as polarity and 
hydrogen bonding capacity. On the other hand, complex 15 and 18 were the most 
hydrophilic. The –CH2 linker between benzoate moiety and carboxylate could 
decrease the rigidity of complex 15 and promote hydrogen bonding. Similarly, the 
presence of lone pairs in the methoxy group of 18 would favor the formation of 
hydrogen bond in the aqueous partition leading to lowered lipophilicity. 
 
With increased lipophilicity, hydrophilicity will be compromised and thus poor 
aqueous solubility would be expected. Generally, the aqueous solubility of the 
asymmetric platinum(IV) complexes followed an inverse relationship with 
lipophilicity. Complex 8 and 13 were the most lipophilic and hence the least 
soluble in aqueous media, with solubility of 0.12 and 0.30 mg/mL respectively. 
Complex 15 and 18 were the most hydrophilic and exhibited the highest aqueous 
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Table 4. Properties of asymmetric platinum(IV) complexes 
aComplexes were dissolved in 8mL of water to saturation and filtered, [Pt] were determined 
through ICP-OES. bLog Pow values were determined through shake flask method using n-octanol 
and ultrapure water. cIC50 is the concentration required to inhibit 50% of cell growth. 
dResistance 
factor is the ratio between the IC50 values of A2780/cis  and A2780. 
 
4.4.4 Evaluating the Anti-Proliferative Properties of the Expanded 
Asymmetric Platinum(IV) Bis-Carboxylates Series 
 
Efficacies of the various platinum (IV) carboxylates were tested on A2780 and 
A2780/cis human ovarian carcinoma cells and compared against cisplatin. IC50, 


















 A2780 A2780/cis 
Cisplatin −2.03 ± 0.47 3.37 ± 0.05 2.56 ± 1.97 27.09 ± 6.35 10.6 
A -0.70 ± 0.02 1.31 ± 0.02 4.50 ± 1.97 19.94 ± 8.27 4.4 
3 –0.28 ± 0.13 0.52 ±0.04 4.25 ± 0.66 16.26 ± 4.18 3.8 
6 –0.08 ± 0.08 0.44 ± 0.00 3.10 ± 0.66 18.40 ± 1.53 5.9 
7 0.28 ± 0.05 0.26 ± 0.06 1.01 ± 0.45 3.75 ± 1.32 3.7 
8 0.46 ± 0.01 0.12 ± 0.01 1.14 ± 0.46 6.52 ± 2.98 5.7 
9 0.19 ± 0.06 0.96 ± 0.02 3.13 ± 0.63 23.02 ± 4.33 7.4 
10 - - - - - 
11 - - - - - 
12 0.13 ± 0.02 0.28 ± 0.01 2.81 ± 1.34 14.72 ± 2.73 5.2 
13 0.56 ± 0.01 0.30 ± 0.01 0.85 ± 0.56 2.30 ± 0.49 2.7 
14 - - - - - 
15 -0.47 ± 0.11 1.52 ± 0.03 9.94 ± 1.89 > 50 - 
16 -0.20 ± 0.01 0.69 ± 0.01 7.32 ± 2.02 30.99 ± 14.39 4.2 
17 0.24 ± 0.02 0.98 ± 0.02 3.83 ± 1.44 13.15 ± 6.48 3.4 
18 -0.41 ± 0.02 1.97 ± 0.02 4.14 ± 0.23 19.09 ± 5.62 4.6 
19 -0.31 ± 0.02 0.18 ± 0.00 6.93 ± 1.25 > 50 - 
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from the mid-point of each graphs plotted in Figure 22, and tabulated in Table 4. 
Asymmetric platinum(IV) bis-carboxylates 7, 8 and 13 exhibited the greatest 
cytotoxicity and were more than 2-folds more cytotoxic than cisplatin against 
A2780 ovarian carcinoma cell line. Complex 7 and 13 exhibited 7 and 9-folds 
increased potency against cisplatin in (A2780/cis) cisplatin-resistance A2780 
variant respectively. These observations were attributed to the increased 
lipophilicity of the platinum(IV) complexes. With improved lipophilicity, the 
complexes can penetrate through the biological membrane more favorably and 
hence improve cellular accumulation leading to enhanced cytotoxicity. Notably, 
complex 7, 8 and 13 were the most lipophilic complexes in the library of 
synthesized compounds. All the synthesized asymmetric platinum(IV) complexes 
exhibited higher lipophilicity than cisplatin, but some of them were less 
efficacious against the tested carcinoma cell lines. This could be attributed to 
slower rates of reduction to yield the active platinum(II) species, resulting in poor 
drug activities. All platinum(IV) prodrugs exhibited cross-resistance to A2780/Cis 
with resistance factors between 2.7 and 7.4, which was significantly lower than 
cisplatin’s resistance factor of 10.6. This cross-resistance phenomena was 
anticipated since both platinum(IV) complexes and cisplatin shared the same 
pharmacophore. However, the structural modifications applied to the 
platinum(IV) scaffolds could have improved uptake of the newly synthesized 
complexes rendering them more bioavailable in vitro. 
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Figure 22. Dose-dependent drug efficacy studies for asymmetric platinum(IV) 
complexes 6-9, 12-13 and 15-19  
 
4.4.5 Investigation for Inter-Dependency Properties within the 
Expanded Asymmetric Platinum(IV) Bis-Carboxylates Series 
 
The anti-proliferative data were taken together with the reduction rates and 
lipophilicities studies to analyze for any discernable inter-dependency properties 
relationship within this library of asymmetric platinum(IV) bis-carboxylates. 
Complex 3, which exhibited t1/2 of 124 min and LogPow of -0.28, was found to be 
comparable to cisplatin in cell inhibition. Although complexes 9 and 12 exhibited 
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greater LogPow than 3, they were not more efficacious than cisplatin due to similar 
reduction rates as 3. On the other hand, complexes 15-18 which showed relatively 
similar LogPow values but lower reduction rates than 3 were less efficacious than 
cisplatin against the tested cancer cell lines. This finding was consistent with 
earlier reports which showed that an intracellular environment could even 
effectively reduce poorly cytotoxic oxoplatin, despite exhibiting high reduction 
potentials.
159, 166
 Interestingly, A was as efficacious as 3 and 18 despite being less 
lipophilic and an order magnitude more readily reducible. A plausible explanation 
could be the rapid reduction of A to yield cisplatin resulting in increased efficacy. 
However, the fast reduction of platinum(IV) mono-carboxylate A would result in 





Only complexes 7, 8 and 13 were more effective than cisplatin against the ovarian 
carcinoma. They were generally more lipophilic and reduced to platinum(II) 
species at a slightly slower rate than 3. While platinum(IV) prodrugs were known 
to undergo cellular uptake via passive diffusion which improves with increased 
lipophilicity and cytotoxicity,
34
 our studies showed that the reduction rates of 
platinum(IV) prodrugs also played an important role in determining the overall 
potency.  
 
Intriguingly, bis-carboxylate platinum(IV) complexes 17 and 18 resisted 
reduction under our assay conditions but exhibited anti-proliferative efficacies 
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that were comparable to cisplatin. The axial phenylbutyrate ligand in 17 is a 
known histone deacetylase inhibitor and can work synergistically with cisplatin to 
influence chromatin remodeling.
167
 On the other hand, methoxybenzoate ligand in 
18 does not have a definitive biological role but its electron-donating substituent 
can decrease the platinum(IV) complex’s susceptibility to reduction while 
preserving its lipophilic character and potency, thus an alternative lead structure 




Asymmetric platinum(IV) bis-carboxylates allow ligands with different properties 
to be accommodated within a common scaffold while preserving the platinum(II) 
pharmacophore. Using axial ligands with contrasting lipophilicity and 
hydrophilicity attributes, we are able to access novel platinum(IV) prodrug 
complexes that are not possible with classical symmetric acylation reactions. This 
strategy can be harnessed to fine-tune the properties of platinum(IV) prodrugs of 
cisplatin and bridge the gap between highly lipophilic and hydrophilic 
platinum(IV) complexes. We showed that in the expanded class of asymmetric 
platinum(IV) bis-carboxylates, lipophilicity and reduction rates are important 
determinant of prodrugs’ anti-proliferative efficacy. This development can pave 
the way for the discovery of new platinum(IV) prodrugs with highly predictable 
and tuned properties for eventual clinical development. 
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4.6 Experimental Procedures 
 
Unless otherwise noted, all procedures were carried out without taking 
precautions to exclude air and moisture. All solvents and chemicals were used as 
received without further treatment. The platinum(IV) complexes used in the 
studies were synthesized as described in Chapter 3. RPMI 1640 medium was 
purchased from Invitrogen (Carlsbad, CA, USA). Penicillin, streptomycin and 
thiazolyl blue tetrazolium bromide (MTT) were all obtained from Sigma 
Chemical Co (St. Louis, MO, USA). Fetal bovine serum (FBS) was from Hyclone 
(Thermo Scientific Inc., Logan, UT, USA). The water used was of Milli-Q grade 
purified by a Milli-Q UV Purification System (Sartorius Stedim Biotech S.A., 
Aubagne Cedex, France). All other solvents and chemicals were of analytical 
grade or HPLC grade obtained from commercial sources. 
 
Instrumentation. UV spectra were recorded on a Shimadzu UV-1800 UV 
spectrophotometer using 1 cm path-length quartz cuvettes. Platinum concentration 
determination was performed using Inductively-Coupled Plasma Optical 
Emission Spectroscopy (ICP-OES) by CMMAC, NUS. Elemental analyses of 
selected platinum compounds were carried out on the Perkin-Elmer PE 2400 
elemental analyzer by CMMAC, NUS. Dual-view Optima 5300 DV ICP-OES 
system was used to determine the platinum content in the aqueous phase. The 
stability and kinetic studies of platinum(IV) compounds were conducted using 
analytical HPLC on a Shimadzu Prominence using a Shimpack VP-ODS C18 (5 
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µM, 120 Å, 250 x 4.60 mm i.d) column at r.t at a flow rate of 1.0 mL/min with 
254 nm and 280 nm UV detection.  
 
LogPow and aqueous solubility determination. The LogPow determination of 
platinum(IV) compounds were conducted using the shake flask method.
168
 
Platinum(IV) compounds were dissolved in 0.9% NaCl w/v ultrapure water (pre-
saturated with n-octanol for 96 h and left to stand overnight). The solutions were 
sonicated and filtered through celite to remove undissolved platinum(IV) 
compounds. The initial concentrations of platinum content were determined by 
ICP-OES to ascentain the maximum solubility of the complexes. Subsequently, 
the platinum(IV) solutions were added an equal volume of n-octanol (pre-
saturated with 0.9% NaCl w/v ultrapure water for 96 h and left to stand 
overnight). The heterogeneous mixtures were shaken vigorously for 2 h before 
centrifuging at 4200g for 15 min to achieve phase separation. The final 
concentration of platinum content in the aqueous phase was determined again by 
ICP-OES and the water-octanol partition coefficient was calculated. All 
experiments were done in triplicates.  
 
Cell Culture. The human ovarian carcinoma cells A2780 and A2780/Cis were 
provided by Prof. Paul Dyson (EPFL). Both cell lines were cultured in complete 
RPMI 1640 medium containing 100 units/mL penicillin, 100 g/mL streptomycin 
and 10% fetal bovine serum. In order to retain resistance, 1 µM cisplatin need to 
be added to the media for A2780/Cis every 2-3 passages. The two cell lines were 





C in a humidified atmosphere of 95% air and 5% CO2. Experiments 
were performed on cells within 10 passages. Viable cells were counted using the 
trypan blue exclusion method. 
 
Inhibition of cell viability assay. Drug effects on exponentially growing tumor 
cells were determined using MTT assay as described previously.
169
 A2780 and 
A2780/Cis cells were seeded at a density of 6,000 cells/100 µL per well in 96-
well plates and incubated for 24 h. Thereafter, tumor cells were exposed to drugs 
at different concentrations in RPMI medium without FBS and antibiotics. 
Compounds were dissolved as DMSO stock solutions and serially diluted with 
DMSO to a series of decreasing concentrations. The final concentration of DMSO 
in medium was 1% (v/v) and such concentration showed little cytotoxicity to both 
strains of cells when incubated for 6 h. The drug-containing medium was 
removed by aspiration, and fresh drug-free complete medium with FBS and 
antibiotics was added and the cells were incubated for additional 66 h. At 72 h 
after drug addition, the medium was aspirated, replaced with 100 µL MTT 
solution (0.5 mg/mL in PBS) and incubated for a further 4 h at 37°C. The medium 
was aspirated and the purple formazan precipitate dissolved in 100 µL DMSO. 
UV-vis absorbance was measured at a 595 nm using a microplate reader (Tecan). 
Experiments were performed in triplicates for each drug concentration and carried 
out independently at least three times. Cytotoxicity was evaluated with reference 
to the IC50 value which was defined as the concentration needed for a 50% 
reduction of survival based on the survival curves. IC50 values were calculated 
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from dose-response curves (cell survival vs. drug concentration) obtained in 
repeated experiments and adjusted to actual [Pt] administered which was 
determined using ICP-OES 
 
DNA-binding studies. Studies on the reaction of platinum compounds with 5’-
dGMP were conducted using analytical HPLC on a Agilent 1200 series DAD 
using a Phenomenex Luna C18 (5 µM, 100 Å, 250 x 4.60 mm i.d) column at r.t at 
a flow rate of 1.0 mL/min with 254 nm and 280 nm UV detection. The gradient 
eluent conditions were as follows: 5-7% solvent A for 20 min followed by 80% 
solvent B for 5 min, where solvent A was NH4OAc buffer (10 mM, pH 7.0) and 
solvent B was MeOH. The purity of platinum(IV) compounds were conducted 
using analytical HPLC on a Shimadzu Prominence using a Shimpack VP-ODS 
C18 (5 µM, 120 Å, 250 x 4.60 mm i.d) column at r.t at a flow rate of 1.0 mL/min 
with 254 nm and 280 nm UV detection. The gradient eluent conditions were as 
follows: 20-80% solvent A for 20 min followed by 80% solvent B for 5 min, 
where solvent A was NH4OAc buffer (10 mM, pH 3.8) and solvent B was MeCN. 
Eluted fractions, besides peaks arising from 5’-dGMP, were collected and 
analyzed by ESI/MS.  
 
Aqueous stability measurement. The synthesized platinum(IV) complexes were 
dissolved in 1 mL of 40 mM HEPES buffer under pH 7.4 in 2 mL microtubes, 
centrifuged and analyzed using analytical HPLC on a Shimadzu Prominence 
using a Agilent ZORBAX Eclipse Plus column (5 μm, 120 Å, 4.60 x 150 mm, 1.0 





 flow) with UV detection at 254 nm and 280 nm. The gradient eluent 
conditions were as follows: 80 % solvent A and 20 % solvent B for first 8 min 
followed by 60 % solvent A and 40 % solvent B for next 7 min. The solvent A 
used was NH4OAc buffer (10 mM, pH 7.4) and solvent B was MeCN. 
 
Kinetics Measurement. The synthesized platinum(IV) complexes were dissolved 
in 1 mL of 40 mM HEPES buffer in 2 mL microtubes, centrifuged and analyzed. 
Redox reactions of the various platinum compounds were conducted using 
analytical HPLC on a Shimadzu Prominence using an Agilent ZORBAX Eclipse 
Plus column (5 μm, 120 Å, 4.60 x 150 mm, 1.0 mL min-1 flow) with UV detection 
at 254 nm and 280 nm. The isocratic eluent conditions were as follows: 60% 
solvent A and 40% solvent B for 10 mins. The experiment was conducted by 
mixing ascorbic acid (100 μL, 30 mM), dissolved platinum(IV) complexes (100 
μL, 1 mM) and HEPES buffer (800 μL, 40 mM, pH 7.4) in a vial. Aliquots of the 
reaction mixtures were injected at regular time interval of 15 minutes. The 
depletion of the platinum(IV) content was monitored up to 500 min. The 
chromatograms were recorded and integrated. The integrated peak areas with 
respect to time were plotted and the time taken for 50 % of platinum(IV) complex 
to be reduced (t1/2) were determined from the graphs.  
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Platinum(IV) prodrugs can be used as phototherapeutic agents by being 
selectively photoreduced using light to release cytotoxic platinum(II) species 
which can bind to DNA.
133
 By irradiating the tumor area with therapeutic dosage 
of light, physical discrimination between diseased and healthy tissue can be 
achieved, enabling unprecedented spatial and temporal control over the treatment 
regimen.  Bednarski et al. first demonstrated this approach using platinum(IV)-
iodo complex containing equatorial iodide ligands (Figure 23) and showed that it 
can be reduced to platinum(II) species upon UV irradiation resulting in the 
dissociation of iodide ligands.
134
 Later on, Sadler et al. showed that the 
replacement of iodide ligands with azide in platinum(IV)-azido complex can 
greatly enhance its photoreductive properties since the dissociated azido ligands 
will irreversibly recombine to nitrogen and will not be able to reoxidise the 
platinum(II) metal centre.
135, 136
 By varying the ammine ligands and their 
positions in the equatorial region, Sadler et al. was able to tune the 
photoactivation of this class of platinum(IV)-azido compounds from short 
wavelength (UVA, 365 nm) to visible blue and green lights.
170
 While it is not 
clear the nature of the platinum(II) species formed,  they react readily with
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nucleosides and DNA which are the putative target of platinum(II) drugs. More 
recently, Natile et al. reported the spontaneous photoreduction of platinum(IV)-
Dach, cis,cis,trans,-[Pt(1,4-Dach)Cl2(OH)2], in visible light to yield parent 
platinum(II) complex cis-Pt(1,4-Dach)Cl2 with concomitant dissociation of the 
axial hydroxide ligands to radicals without the presence of any photoactive agents 
such as azido or iodide ligands.
171
 The hydroxide radicals quickly recombined to 





Taken together, we hypothesize it will be possible for platinum(IV) bis-
carboxylates to  incontrovertibly yield cisplatin through cleavage of the axial Pt-O 
bonds upon photoreduction. The carboxylate ligands should have significant UV 
absorption cross-section and be able to stabilize departing radical species. Based 
on these considerations, we investigated the photoractivatable properties of bis-
carboxylated platinum(IV) complexes 1-3 under photolytic conditions using UV 
as a light source (Figure 23). Complexes 1 and 3 bear aromatic benzoate ligands 
in the axial positions which can act as chromophores to absorb the light while 2 
does not contain any aromatic chromophore and was used as a control to validate 
our hypothesis. To investigate the tunable UV absorption parameter of this class 
of asymmetric platinum(IV) bis-carboxylates, complexes I, 20 and 21 were 
designed and studied (Figure 23). 
 
 




Figure 23. Chemical structure of platinum(IV) complexes investigated for their 
photoactivatable properties  
 
5.2 Evaluating the Photoreducibility of Platinum(IV) Bis-
Carboxylates 
 
Structurally, 1 and 3 differ from 2 with the incorporation of at least an axial 
benzoate ligand. Due to its poor aqueous solubility, photoreduction of 1 was 
carried out in acetone by irradiating it at 365 nm using a standard handheld 16W 
laboratory UV lamp held 5 cm away. Within 5 min of irradiation, precipitation of 
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an off-white compound could be visually observed which was completed after 60 
min. TLC analysis of the residual solvent phase indicated the conversion of 1 to a 
hydrophobic compound exhibiting a similar Rf to benzoic acid. The isolated 
precipitate, on the other hand, was highly polar and exhibited moderate aquatic 
solubility. The ESI-MS spectrum of the precipitate in aqueous solution showed 
distinct peaks at m/z 335, 635 and 935 in the –ve mode, corresponding to 
molecular ions of cisplatin and its aggregates [Cisplatin+Cl]
-
, [2Cisplatin+Cl]-, 
and [3Cisplatin+Cl]- respectively. In order to confirm the identity of the 
isolated platinum precipitate, we carried out 
195
Pt NMR analyses of the sample in 
DMSO-d
6
. Reduction of platinum(IV) to platinum(II) is accompanied by a change 
in the coordination sphere of complex 1 and decreases from 6 coordinated ligands 
to 4. The platinum chemical shift is highly sensitive to the ligand environment and 
platinum oxidation state with cisplatin and oxoplatin exhibiting resonances at ca.  
-2148 ppm and 853 ppm respectively. On the other hand, the resonance 
attributable to complex 1 was more deshielded and appeared at 1110 ppm due to 
the presence of the electron-withdrawing benzoate ligands. The isolated 
precipitate exhibited a resonance peak at -2144 ppm (Figure 24), which was 
consistent with the chemical shift of cisplatin and in stark contrast to 1. These 
results support the initial hypothesis that platinum(IV) prodrugs of cisplatin 
bearing bis-aryl carboxylates in the axial positions will undergo reduction under 
UV irradiation to yield cisplatin. As far as we know, this represents the first 
example of a platinum(IV) prodrug which yields cisplatin after photoactivation.  






Pt NMR spectra of cisplatin, and complex 1 before and after UV 
 
To further understand the nature of the photoactivation process, time-dependent 
1
H NMR studies was conducted to study the effect of UV irradiation on 1 at 
different time intervals in deuterated acetone solvent (Figure 25). Upon irradiation 
at 365 nm, the multiplet attributable to the NH3 ligands at ca. 6.5 ppm gradually 
diminished as the precipitate separated from the solvent. The most downfield peak 
at 7.99 ppm corresponding to the ortho-benzoate protons reduced in intensity with 
the appearance of two new sets of doublets that were more downfield. Of these 
two sets of doublets, one eventually dissipated leaving the other doublet at 8.04 
ppm after prolonged irradiation. Resonances attributable to the meta and para-
aryl protons underwent similar downfield shifts while the diammine peaks at 6.70 
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ppm gradually disappeared. Photoconversion was completed after 60 min of UV 
irradiation.  
 
Based on these observations, we postulated that UV irradiation induced the 
dissociation of the axial benzoate ligands from the platinum(IV) scaffold. This 
could be accomplished via homolytic photocleavage of the Pt-O bond, yielding 
hydrophilic cisplatin as the precipitate, as well as two molar equivalents of 
benzoate radicals. These benzoate radical intermediate species formed were 
rapidly quenched by residual HOD to form the benzoic acid, evidenced by the 
decrease in intensity of the HOD resonance at c.a. 2.8 ppm and the appearance 
and dissipation of the most downfield peak corresponding to the ortho-benzoate 
radical protons over the course of the reaction. Formation of the benzoic acid 
product was also earlier observed using TLC analyses.  
 
Figure 25. Effect of irradiation of UV light at 365 nm on 
1
H NMR spectra of 
complex 1 after 0, 5, 15, 30, 45, and 60 min 
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Asymmetric platinum(IV) bis-carboxylate 3 was also dissolved in deuterated 
water solvent and subjected to UV irradiation at 365 nm and the photoreduction 
was observed at regular time intervals on 
1
H NMR (Figure 26). The 
photoreduction was completed only after 120 min with no precipitate formed. A 
plausible argument could be during the photoreduction of 1 in acetone-d6, 
cisplatin was being precipitated as the by-product. Hence, the equilibrium was 
shifted right by Le Chatelier’s principle which led to fast completion of the 
photoreduction.  Another reason could be the presence of two benzoate ligands in 
1 which were good chromophores for the UV irradiaton while 3 only had one 
benzoate ligand, which resulted in 3 absorbing UV irradiation slower and hence 
photoreduced at a slower rate. In the 
1
H NMR spectra, the diammine protons 
which reasonate at c.a. 6.5 ppm was absent due to deuterium exchange with the 
solvent. Upon irradiation, the most downfield peak at 7.86 ppm corresponding to 
the ortho-benzoate protons gradually diminished in intensity with the appearance 
of only one set of doublets at 7.92 ppm. Resonances attributable to the meta and 
para-aryl protons underwent a similar shift from 7.50 and 7.39 ppm to 7.57 and 
7.45 ppm, respectively, while the acetyl protons peak at 2.06 ppm also decreased 
in intensity with the appearance of a new set of singlet at 2.00 ppm. The 
formation of radicals could occur during photoreduction. In the presence of water 
molecules in D2O solvent, the benzoate and acetate radicals rapidly formed 
benzoic acid and acetic acid with the electrophilic H
+
, which could explain why 
no radical intermediates were observable in the 
1
H NMR spectra. However, the 
reaction of the radicals with water molecules could be observed from the 
1
H NMR 
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Figure 26. Effect of irradiation of UV light at 365 nm on 
1
H NMR spectra of 
complex 3 after 0, 15, 30 and 120 min in D2O solvent 
 
Complex 2 was also dissolved in D2O solvent and subjected to UV irradiation at 
365 nm to prove our hypothesis that an aromatic chromophore is required for the 
photoreduction of platinum(IV) complexes to proceed. Surprisingly, it was found 
to undergo reduction under irradiation, albeit at a slower rate from the 
1
H NMR 
studies. Similar to the previous observations, the singlet at 2.04 ppm 
corresponding to the acetyl protons of 2 gradually diminished in intensity with the 
appearance of a new singlet at 2.00 ppm. However, it was observed that the 
photoreduction of 2 was incomplete after 180 min of UV irradiation (Figure 27), 
leading to conclusion that having chromophoric ligands in the axial position of 
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platinum(IV) complexes do increase of rate of reduction, whereby the rate can be 
tuned by varying the number of chromophoric ligands. 
 
 
Figure 27. Effect of irradiation of UV light at 365 nm on 
1
H NMR spectra of 
complex 2 after 0, 15, 30, 45, 90 and 180 min in D2O solvent 
 
Unlike 1 where cisplatin was qualitatively isolated and analysed, we were unable 
to conclusively determine the identity of the reduced platinum(II) species formed 
for 2 and 3 as no cisplatin was observed from ESI-MS and 
195
Pt NMR.  
Nonetheless, we postulated that the platinum(II) species formed would either be 
cisplatin hydrolysed species or platinum(II) species bearing cisplatin 
pharmacophore [cis-Pt(NH3)2].    
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5.3 Evaluating the Photoactivation of Platinum(IV) Prodrugs 
by UV irradiation 
 
To unanimously determine the formation of platinum(II) species upon 
photoreduction of platinum(IV) complexes, a fluorescent probe, Rho-DDTC, that 
was previously reported was used.
172
 The fluorescent turn-on probe was found to 
be selective enough to distinguish between platinum(IV) and platinum(II) within a 
complex cellular environment as the probe only fluoresces when bound to 
platinum(II) species. A standard curve was obtained to quantify the amount of 
platinum(IV) reduced using cisplatin and 30 µM of Rho-DDTC in HEPES buffer 
(20 mM, pH 7.4, 30% ethanol) (Figure 28). Various concentrations of cisplatin (0-
90 µM) were mixed in 30 µM of Rho-DDTC in HEPES buffer overnight and the 
fluorescence measured. The fluorescence intensity was found to increase linearly 
before reaching a plateau at 60 µM of cisplatin concentration.  Hence, 50 µM of 
complexes 1-3 were subjected to photo-irradiation at 254 and 365 nm for up to 2 
hours before mixing with Rho-DDTC at various time intervals to determine the 
amount of platinum(IV) reduced and the results depicted in Figure 29. All 
platinum(IV) complexes tested displayed little or no change in fluorescence 
intensity when stirred overnight with the Rho-DDTC. Upon UV irradiation to 
induce photoreduction of the platinum(IV) complexes, the Rho-DDTC showed an 
increased in fluorescence intensity.  
 
From the data obtained, complex 1 was reduced to platinum(II) within 0.5 hour 
upon UV irradiation at 254 nm, and within an hour at 365 nm. 58±3 % of 
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complex 2 was reduced to platinum(II) after 0.5 hour before proceeding to 96±4 
% after 1.5 hours of UV irradiation at 254 nm. Upon UV irradiation at 365nm, 
only 28±5% of 2 was reduced to platinum(II) after 1 hour, before increasing to 
32±2% after 2 hours (Figure 29). UV irradiation on 3 resulted in 92±2% reduced 
to platinum(II) after 0.5 hour before proceeding to 100% within 1 hour of UV 
irradiation at 254 nm, while 47±6% of 3 was reduced to Pt(II) species in 1 hour 
before proceeding to 100% after 2 hours when irradiated at 365 nm. The 
wavelength for maximum absorption (λmax) of the platinum(IV) complexes 1-3 
were 232, 204 and 226 nm respectively, and their molar extinction coefficients (ε) 
at 6.0 µM concentration were 5.71 x 10
5
, 1.19 x 10
5







(Table 5).  
                       
Figure 28. Standard curve depicting the increasing fluorescence intensity with 
increasing concentration of cisplatin 
 




Figure 29.  Chart depicting the increase in fluorescence intensity of platinum(IV) 
complexes 1-3 upon UV irradiation at (a) 254 nm and (b) 365 nm 
 
These results indicate that the presence of aromatic pharmacophores are essential 
for photoreduction of platinum(IV) to platinum(II), especially when irradiated at 
wavelength significantly higher than their λmax. The photoreduction rates are 
faster when the compounds were irradiated at 254 nm than 365 nm. Evidently, 
increasing conjugation of the platinum(IV) complexes will lead to a red shift in 
the λmax, a better absorption of the UV irradiation and a faster rate of 
photoreduction. We postulate we can rationally design asymmetric platinum(IV) 
bis-carboxylates with λmax near 365 nm so as to tune their absorption spectrum 
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Table 5. UV-Vis spectroscopy data of platinum(IV) complexes 
Complex λmax (nm) ε (M
-1cm-1) 




 204 1.19 x 105 
3 226 1.93 x 10
5 
I 345 6.18 x 10
6 
20 344 6.31 x 10
6 
21 345 6.36 x 10
6 
bUV-Vis spectroscopy data was obtained in aqueous solution. The rest of the data were obtained in 
acetonitrile solution. Concentration of the platinum(IV) complexes were adjusted to 6.0 µM before 
measurements. 
 
5.4 Evaluating the Tunable Photoactivatable Properties 
Asymmetric of Platinum(IV) Bis-Carboxylates 
 
Platinum(IV) complexes I and 20-21 (Figure 23) containing a pyrene moiety in 
the axial position to increase their aromaticity and λmax were synthesized (Chapter 
3) and investigated for their photoactivatable properties. The distance from the 
electron withdrawing pyrene moiety was increased with a propyl chain so as to 
decrease the rate of intracellular reduction, which was previously observed in 
Chapter 4. This was to ensure that majority of the platinum(IV) complexes I and 
20-21 remained in their inert platinum(IV) forms, before photoactivated by UV 
irradiation to yield cytotoxic platinum(II) species at the tumor sites.  The ligand in 
the other axial position was varied to investigate the effect on overall absorption 
spectrum and reduction rates of the prodrugs. Bearing the cisplatin core, the 
platinum(IV) prodrugs were expected to photoreduce to cisplatin upon UV 
irradiation. 
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Extensive conjugation in the pyrene functional group also allowed the 
platinum(IV) compounds to absorb strongly at ~345 nm (λmax)  (Table 5), which 
was close to the UV irradiation at 365 nm. These absorption peaks corresponded 
to the π → π* electronic transition of pyrene with different vibrational energy 
levels at this electronic state. The presence of hydroxyl or carboxylate ligand on 
the other axial position had negligible effect on the λmax. However, there was an 
slight increase in the molar extinction coefficient, ε, of asymmetric platinum(IV) 
bis-carboxylates 20 and 21 when compared to platinum(IV) mono-carboxylate I. 
In comparison, platinum(IV) complexes I and 20-21 were able to exhibit 
significantly higher λmax and ε than 1-3 by substituting the axial ligand with a 
more conjugated aromatic molecule. This validated our approach of tuning the 
photoactivatable properties of platinum(IV) prodrugs through asymmetric 
carboxylation. 
 
5.5 Evaluating the Photoactivation of Asymmetric 
Platinum(IV) Bis-Carboxylates by UV irradiation 
 
To ascertain that UV irradiation can photoreduce the platinum(IV) prodrugs, 
complexes I and 20-21 in DMF:H2O (1:1 v/v) solution were exposed to UV 
radiation (365 nm) for 0.5 hour. The UV absorption spectra of the complexes 
showed a decrease in the peaks corresponding to ~345 nm indicating the 
dissociation of the pyrene ligand upon photoactivation (Figure 30). 




Figure 30. UV absorption spectrum of complex 21 before and after UV 
irradiation at 365 nm 
 
 
Thin layer chromatography (TLC) was subsequently used to test for the presence 
of 1-pyrenebutyric acid formed upon reduction. Significant fluorescence intensity 
of 1-pyrenebutyric acid, which was initially quenched by platinum(IV) metal 
centre,
173
  was observed on the TLC plate based on Rf value after photoreduction. 
Previously, the formation of benzoic acid that was observable on the TLC plate 
upon photoreduction of 1 did not exhibit any fluorescence. Hence, fluorescence 
measurements were taken to study the rate of reduction for complexes I and 20-
21. Equimolar solutions of I and 20-21 in 1:1 v/v ratio of DMF:H2O solutions 
were exposed to UV irradiation at 365 nm for 2 hours. At specified time intervals, 
the amount of 1-pyrenebutyric acid formed was monitored by fluorescence 
measurements using an excitation wavelength of 343 nm that corresponded to the 
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λmax of pyrene. Fluorescence measurements of 1-pyrenebutyric acid showed 
complex 20 was photoreduced the fastest followed by I (Figure 31). The 
fluorescence intensity of 1-pyrenebutyric acid upon UV irradiation of 20 reached 
a plateau at 100 min. The plateau corresponded to the maximum amount of 1-
pyrenebutyric acid that could be generated, which indicated complete reduction of 
the platinum(IV) complex. UV irradiation of I reached a similar level of 
fluorescence intensity at 100 min with a slower initial rate of reduction, while that 
of 21 had attained complete reduction after 2 hours. Surprisingly, the reduction 
rates of I and 20-21 were slower than 4 (Figure 29) despite having a stronger 
pyrene chromophore resulting in higher λmax and ε. This was likely due to a more 
stable Pt-Opyrene bond as compared to Pt-Obenzoate due to the presence of propyl 
hydrocarbon linker leading to increased bond distance between pyrene and 
platinum(IV) metal center. 
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Figure 31. Fluorescence intensities at the maximum emission wavelength, 
378nm, taken at specified times after initial UV irradiation of complexes I and 20-
21 
One of the limitations using this class of platinum(IV) bis-carboxylate is the 
potential for them to undergo cellular reduction upon cell entry, although the 
reduction rate can be slowed significantly by increasing the bond distance 
between the electron withdrawing aryl moiety and platinum(IV) metal center. 
Another limitation will be the requirement of irradiation with shorter wavelength 
(365 nm) to photoactivate the platinum(IV) prodrugs which will limit its clinical 
applications,
174
 as UV radiation has very limited penetration depth in biological 
tissues and can cause significant damage to DNA by inciting adjacent thymine 
pairs to form thymine dimers which replication polymerase cannot recognize.
137
 
However, this can be mitigated by further fine-tuning of the λmax with more 
conjugated chromophores. Nonetheless, a potential platinum(IV) prodrug strategy 
will be to encapsulate the platinum(IV) carboxylates in nano carriers which can 
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only be released as active platinum(II) species under photolytic conditions. As 
mentioned in Chapter 1, Xing et al. had conjugated a photoactivatable 
platinum(IV) complex to upconversion nanoparticles (UCNPs) that can convert 
NIR to UV light, leading to the reduction of the platinum(IV) complex (Scheme 
10). Henceforth, the encapsulation of our series of platinum(IV) bis-carboxylates 
in UCNPs as a photoactivation of platinum(IV) prodrugs strategy will be of our 
main interest in overcoming the current limitations and is the subject of new 









In summary, we have investigated a new class of photoactive platinum(IV) 
complexes containing benzoate ligands by design. The benzoate leaving groups 
are positioned at the axial ligand sites, in contrast to other examples, with the goal 
of yielding cisplatin upon ligands dissociation. Our evidences suggested that the 
                                                                                                             Chapter 5 
121 
 
benzoate ligands on 1 were heterolytically cleaved from the platinum(IV) 
scaffold, resulting in its conversion to cisplatin, demonstrating for the first time 
that a photoreductive cisplatin-prodrug is possible. In addition, we showed that 
the photoreductive property of platinum(IV) complexes can be fine-tuned by 
replacing the benzoate ligands with a more conjugated pyrene moiety. We are 
optimistic that by further tuning the nature of the axial ligands, we can extend the 
strategy to identify other photoreductive platinum(IV) complexes that will 
generate exclusively cisplatin upon activation. 
 
5.7 Experimental Procedures 
 
Unless otherwise noted, all procedures were carried out without taking 
precautions to exclude air and moisture. All solvents and chemicals were used as 
received without further treatment. The platinum(IV) complexes used in the 
studies were synthesized as described in Chapter 3. The water used was of Milli-
Q grade purified by a Milli-Q UV Purification System (Sartorius Stedim Biotech 
S.A., Aubagne Cedex, France). All other solvents and chemicals were of 






Pt NMR spectra were recorded on a Bruker ACF 
300 and Bruker AMX 500 spectrometer and the chemical shifts () were 
internally referenced by the residual solvent signals relative to tetramethylsilane 
for 
1
H and externally referenced using K2PtCl4 for 
195
Pt. Mass spectra were 
measured using a Bruker Ultimate 3000 ion trap ESI mass spectrometer. UV 
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spectra were recorded on a Shimadzu UV-1800 UV spectrophotometer using 1 
cm path-length quartz cuvettes. Fluorescence measurements were performed 
using Synergy H1 hybrid multi-mode microplate reader from Biotek. The 
ultraviolet light source used for photochemical studies was a ZF-7A model 
handheld UV lamp with a power rating of 16W. It can operate with two different 
wavelengths of 254 nm and 365 nm respectively. The photochemical studies 
described were all conducted using UV light of 254 and 365 nm. The 
platinum(IV) complexes were irradiated at a distance of 5 cm from the UV lamp. 
 
Turn-on fluorescence probe by cisplatin. Rho-DDTC was prepared as a 10 mM 
stock solution in DMSO and diluted in HEPES buffer (20 mM, pH 7.4, 30% 
ETOH) to obtain a concentration of 60 µM. 50 µL of the Rho-DDTC solution was 
mixed with 50 µL of cisplatin to obtain 15.0, 22.5, 30.0, 37.5, 45.0, 60.0, 75.5 and 
90.0 µM of cisplatin respectively. The solution mixtures were incubate at 37
o
C 
ovenight and the fluorescence intensity recorded at em = 584 nm (ex = 490 nm). 
A standard curve of fluorescence intensity against concentration of cisplatin was 
plotted from the data obtained. This experiment was repeated in triplicates. 
 
Activation of Pt(IV) complexes. Complex 1 was dissolved in acetone while 2 
and 3 were dissolved in HEPES buffer solution respectively. These platinum(IV) 
solutions were irradiated with UV at 254 and 365 nm for up to 2 hours before 
mixing with prepared Rho-DDTC solution overnight at 37
o
C. The amount of 
platinum(II) species formed via photoreduction of platinum(IV) were determined 
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by measuring the fluorescence intensity and subsequently derived from the 
standard curve equation from cisplatin. 
 
Quantitative evaluation of the reduction of platinum(IV) complexes by UV 
irradiation. Platinum(IV) complexes I and 20-21 (6.0 μmol each) were dissolved 
in  1:1 v/v ratio of DMF:H2O solution (1.2 mL). The mixtures were contained in 
quartz cuvettes and subjected to UV irradiation (365nm). At regular time intervals 
(0, 10, 20, 30, 40, 50, 60, 80, 100, 120min upon UV irradiation), a fixed volume 
of platinum(IV) complexes solutions (2x100μL each for triplicate measurements) 
were pipetted out onto a 96-well plate. After 120 min, fluorescence measurements 
were performed on the 96-well plate with the solutions with a gain setting of 70, 





Targeted Delivery of Dual-Drugs using Asymmetric 
Platinum(IV) Bis-Carboxylates Entrapped in Multi-




Cisplatin is limited by high toxicity and severe side-effects as well as 
incidences of platinum-associated drug resistance.
22
 To overcome these 
limitations, cisplatin has been investigated in combination with 
anthracycline-based topoisomerase II (TOP2)-inhibitors against human lung 
cancer cell lines and found to greatly enhance the overall activity.
175, 176
 
TOP2 inhibitors intercalate duplex DNA and the resultant DNA-adducts 
formed inhibit the progression of TOP2 in the process of DNA remodelling. 
Because this pathway is independent of DNA alkylation damage induced by 
cisplatin, the cellular repair mechanisms can be overcome when TOP2 
inhibitors are used together with cisplatin.
177, 178, 179
 A recent Phase III 
clinical trials found that overall therapeutic efficacy was improved with a 
significantly higher response rate when cisplatin was co-administered with 
doxorubicin (Doxo, Figure 33), a TOP2 inhibitor, against endometrial 
adenocarcinoma.
180
 Doxo:cisplatin combination regimens have also been 
evaluated in other clinical trials against several other malignancies with 
positive results. In these therapies, patients were dosed




with Doxo:cisplatin ratios of between ca. 0.9 to 3.0 molar equivalents 
cisplatin with respect to Doxo.
180, 181, 182, 183, 184
 
 
There are however unique challenges involved in delivering drug 
combinations in a clinical setting,
185
 as the drugs usually exhibit different 
pharmacokinetics properties resulting in uneven distribution of final 
concentrations at the intended target. Therefore, it is difficult to control the 
constituent drug levels of the combination regimen as well as coordinate 
their delivery to the site of action. . To ensure accurate control over the drug 
compositions, it is rationale to conjugate therapeutic drugs to the axial 
positions of platinum(IV) prodrug of cisplatin as a dual delivery of two 
drugs simultaneously. Upon reaching the tumor site, the platinum(IV) 
prodrug will undergo reduction to release cisplatin and therapeutic drug to 
yield the intended dosages. However classical synthetic strategy can only 
allow the development of symmetric platinum(IV) bis-carboxylates with no 




To demonstrate the viability of delivering ratiometric equivalent of cisplatin 
and doxorubicin, a novel asymmetric bis-carboxylate platinum(IV)-Doxo, 
23, was rationally designed (Figure 33). To achieve tumor-targeting, 23 was 
entrapped in multi-walled carbon nanotubes (MWCNT) whose surface were 
functionalized integrin-targeting cyclic peptide c(RGDfK). Previously, we 
reported the stable entrapment of lipophilic symmetric platinum(IV) bis-




carboxylate 1 with the MWCNT cavities through hydrophobic-hydrophobic 
interactions.
122
 Henceforth, the lipophilicity of 23 was tuned by adding a 
hydrophobic benzoate moiety to the other axial position so as to achieve 
favourable drug loading into MWCNT. 
 
This anticancer strategy is centred on the intracellular reduction of an inert 
platinum(IV) prodrug, that is stably entrapped within the MWCNT due to 
hydrophobic-hydrophobic interactions, which simultaneously releases exact 
ratiomeric equivalent of hydrophilic cisplatin and Doxo upon cell entry 
(Figure 34). The formulation of MWCNT-platinum(IV) prodrug 
nanoconjugate capable of synchronous ratiometric delivery of two 
mechanistically complementary drugs and its anti-proliferative efficacy 
against ovarian and endometrial cancer cells will be discussed in greater 
details in the ensuing section. 






Figure 33. Chemical structure of doxorubicin (Doxo), c(RGDfK), and 
asymmetric carboxylate platinum(IV)-Doxo conjugate, 23  
 
 
Figure 34. Concept of ratiometric dual-drug delivery via hydrophobic entrapment 
using MWCNT as nanocarrier 
 
 




6.2 Synthesis and Characterization 
 
6.2.1 Asymmetric Platinum(IV) Bis-Carboxylate 23 
 
To synthesize 23, asymmetric platinum(IV) complex 22 bearing a free 
carboxylic function group in the axial position was prepared (Chapter 3). 
Complex precursor 22 was coupled to Doxo in DMF with O-benzotriazole-
1-yl N,N,N',N'-tetramethyluronium hexafluoro-phosphate (HBTU) as a 
coupling reagent under room conditions to yield 23 (Scheme 14a). The 
product 23 was recovered from the crude reaction mixture via lyophilisation 
to remove the non-volatile DMF solvent, followed by repeated washing 
using water, acetone and diethyl ether. Previous attempts to synthesize 23 
using N,N’-dicyclohexylcarbodiimide (DCC) and 
ethyl(dimethylaminopropyl)-carbodiimide (EDC) as coupling reagents 
resulted in poor yields. Complex 23 was characterized using ESI-MS and 
1
H NMR spectroscopy, and its purity determined by elemental analysis. The 
parent molecular ions [M-H]
-
 were readily observed using ESI-MS. 
Fragmentation analysis for 23 resulted in the loss of the Doxo ligand, 
consistent with the proposed structures. Characteristic resonances could be 
observed at ca. 6.6 ppm in 
1
H NMR, assigned to the ammine ligands, which 
was consistent with previous platinum(IV) bis-carboxylates. The formation 
of 23 was also indicated by the disappearance of the –COOH proton at 12.0 
ppm, which was present in 
1
H NMR of 22. In addition, the integral value in 
1
H NMR showed that there was only one unit of Doxo with respect to the 
ammine ligands.  




6.2.2 MWCNT-Platinum(IV) Prodrug Nanoconjugate 
[23·MWCNTc(RGDfK)] 
 
To achieve tumour-targeting, c(RGDfK) peptide was conjugated to the 
MWCNT platform (Scheme 14b). These peptides recognize multiple 
ligands of αv integrin family,
187
 and have been found to exhibit high affinity 
to αvβ3 and αvβ5 integrin receptors that are overexpressed in tumor 
angiogenic endothelial cells.
188, 189
 Hence, they are particularly relevant for 
endometrial adenocarcinomas since vascular endothelial growth factor, 
which is correlated with angiogenesis, is the major stimulus for endothelial 




Ultrapure (≥98%) MWCNTs with a diameter of 30-40 nm and a length of 
up to a few µm were used given their higher internal loading capacity 
compared to single-walled CNTs (SWCNTs). These pristine MWCNTs 
were oxidized and purified in accordance to a reported procedure to yield 
MWCNToxidized (Scheme 14b),
191
 and coupled with bifunctional 2,2’-
(ethylenedioxy)diethylamine (TEG) using EDC/DIPEA to obtain amine-
terminated MWCNTs (MWCNTTEG). Quantitative Kaiser Test was 
performed to determine the degree of amino-functionalization on 
MWCNTTEG and ascertained to be 680 µmol of -NH2 groups per gram of 
MWCNTs. The purified and dried MWCNTs were subsequently treated 
with excess of succinic anhydride in DMSO at r.t. for 3 days to form 
carboxylic acid-terminated MWCNTs (MWCNTTEG-COOH). A negative 




Kaiser Test indicated that the amine groups on the MWCNTs were fully 
converted to carboxylic acid functional groups.  
  
MWCNTTEG-COOH was subsequently coupled to c(RGDfK) peptide using 
HBTU/NEt3 to obtain MWCNTc(RGDfK) (Scheme 14b). The formation of 
MWCNTc(RGDfK) was accompanied by a mass change of more than 50%. For 
hydrophobic entrapment, purified MWCNTc(RGDfK) was suspended with 23 
in solvent and agitated for 3 days in accordance with a previously reported 
procedure.
192
 Water or CHCl3 was used as the drug entrapment solvent for 
nanoextraction since they poorly solubilized both 23 and MWCNTc(RGDfK) 
and would enhance their hydrophobic-hydrophobic interactions. The 
entrapped product [23·MWCNTc(RGDfK)] was filtered and washed 
extensively with a washing solvent mixture comprising water:CHCl3:MeOH 
(1:2:2.5 v/v). This washing step was essential to remove unbound 23 on the 
external MWCNT surface without displacing those entrapped within the 
core. Being intensely red in colour, complete removal of unbound 23 was 
indicated by clear washings and restoration of the MWCNTs as a black 
residue. 






Scheme 14. Synthetic scheme for (a) preparation of 23 and (b) surface 
functionalization of MWCNT to yield MWCNTc(RGDfK) 
 
 
Platinum content in [23·MWCNTc(RGDfK)] was determined using ICP-OES 
on samples that were incinerated at 1000ºC and their residues reconstituted 
in 2% HNO3. Based on the platinum levels quantitated, the entrapment 
levels within MWCNTc(RGDfK) using CHCl3 and water as solvent systems 
were ascertained to be 17.0±1.0% and 24.5±0.8% w/w of 23, respectively. 
In previous reports, entrapment efficiencies of cisplatin and 1 in 
MWCNToxidized were higher at 62.1±2.0% w/w and 51.7±2.0% w/w, 






The lower [23·MWCNTc(RGDfK)] loading was presumably 
due to its increased steric encumbrance, resulting in poorer mobility within 
the MWCNT cavity.  
 
6.3 Evaluating the Anticancer Properties of 
[23·MWCNTc(RGDfK)] 
 
6.3.1 Stability and Kinetic Properties 
 
To achieve targeted delivery, drug payload should only be released at the 
site of its intended target. To demonstrate that [23·MWCNTc(RGDfK)] can 
function effectively as a delivery platform for controlled release of its 
payload, we investigated the stability of 23 entrapped within MWCNTTEG 
under reducing and non-reducing aqueous conditions. For comparison, we 
prepared entrapped Doxo and monitored its release from MWCNTTEG using 
UV-vis spectroscopy (550). Under aqueous conditions, Doxo was released 
rapidly from MWCNTTEG with >50% of the payload released within 10 
hours (Figure 35). Complete drug release was achieved after 4 days. 
Entrapped 23, on the other hand, was stable within MWCNTamine and 
uncontrolled release of Doxo into the surrounding environment was not 
observed. Only after 4 days was ca. 10% Doxo w/w non-specifically 
released into the media. However, in the presence of chemical reductant, i.e. 
3 mM ascorbic acid, release of Doxo was observed culminating with 
complete release after 4 days. In this manner, controlled release of the 
hydrophobically entrapped drug payload was achieved using reduction of 




the platinum(IV) scaffold. Chemical reduction by ascorbic acid reduced the 
platinum(IV) prodrug to platinum(II) while liberating its axial ligands, 
namely benzoate and Doxo-succinate. Because these components are 
hydrophilic, they could not be stably entrapped within MWCNTs and were 
discharged.  
 
Figure 35. Release of Doxo from MWCNTTEG monitored using UV-vis 
spectroscopy (550) 
 
6.3.2 Anti-Proliferative Property 
 
The anti-proliferative efficacy of the new constructs on the growth 
inhibition of Ishikawa endometrial adenocarcinoma as well as A2780 and 
A2780/Cis human ovarian carcinoma cells was investigated (Table 6). To 
mitigate the effects of contamination, platinum concentration of the stock 
solutions were determined using ICP-OES and the IC50 values were 
adjusted to actual platinum concentration values for entries 1, 3, 4 and 6.  




Cisplatin exerts its cytotoxic effects through DNA alkylation which yield 
primarily intrastrand platinated adducts on purine bases,
161
 while Doxo, a 
DNA intercalator, prevents the progression of TOP2 during DNA 
remodelling leading to stalling of TOP2 at the adduct site.
193
 Due to these 
complimentary mechanisms acting on the same biological target, we 
postulated that a combination of these drugs could lead to synergistic 
enhancement of cytotoxicity. As anticipated, Doxo exerted a strong 
cytotoxic effect against both A2780 and A2780/Cis indicating that its mode 
of action is independent of the cisplatin resistance pathway. We further 
noted that a 1:1 combination of cisplatin and Doxo was additive which 
could be due to differential uptakes of the two drugs. The construct 
[23·MWCNTc(RGDfK)] contained a platinum(IV) prodrug that was capable of 
delivering cisplatin and Doxo in stoichiometric-equivalent portions. 
[23·MWCNTc(RGDfK)] was more efficacious against the tested cell lines 
compared to cisplatin, Doxo or a physical mixture of cisplatin + Doxo (1:1). 
In keeping with Doxo, [23·MWCNTc(RGDfK)] was also able to overcome 
A2780/Cis. Strikingly, against target Ishikawa endometrial adenocarcinoma 
cells, [23·MWCNTc(RGDfK)] was ca. 2-fold more cytotoxic than either Doxo 
or cisplatin + Doxo 1:1 combination and 11-fold more than cisplatin alone. 
The IC50 values of [23·MWCNTc(RGDfK)] was compared with pure 23 
against these cell lines. We noted that at these concentrations, blank 
MWCNTc(RGDfK) was non-cytotoxic (Table 6, entry 5). In all instances, 
[23·MWCNTc(RGDfK)] was 4-7 fold more cytotoxic than the free 23, 




indicating that the MWCNTc(RGDfK) platform was crucial for delivering the 
payload to the cancer cells. 
 
6.3.3 Platinum Uptake in Ishikawa Cells 
 
Therefore, we treated Ishikawa cells with 23 and [23·MWCNTc(RGDfK)] for 
6 hours and quantitated the cellular platinum levels using ICP-MS to study 
the effect of the MWCNT construct on the drugs’ efficacies. Cells treated 
with [23·MWCNTc(RGDfK)] exhibited ca. 3-fold higher platinum levels 
compared to those treated with 23 alone (Figure 36), demonstrating the 
excellent internalization of hydrophobic 23 by our MWCNT constructs. 
 
Table 6. IC50 values (µM) against cancer cell lines
a
 
Entry Test compoundb A2780 A2780/Cis Ishikawa 
1 Cisplatin  1.71  0.42 13.11  1.99 11.10  0.80 
2 Doxo 0.92  0.48 0.89  0.15 2.96  0.15 
3 Cisplatin + Doxo (1:1) 0.84  0.02 1.17  0.11 2.35  0.25 
4 23 3.29  0.72 4.82  0.28 6.76  0.44 
5 [MWCNTc(RGDfK)]
c >50 >50 >50 
6 [23·MWCNTc(RGDfK)] 0.76  0.17 0.90  0.30 0.95  0.06 
aConcentration required to inhibit 50% of the cell growth with respect to control groups, 
measured by MTT assay after 72 h exposure. bData obtained are based on the average of at 
least three independent experiments with the corresponding standard deviations. cEmpty 
MWCNTc(RGDfK) were tested and inhibition of cell viability was not observed at >50 µg/mL 




                 




                  
 
Figure 36. Platinum content of Ishikawa cell extracts after treatment with 
MWCNTc(RGDfK), 23 and [23·MWCNTc(RGDfK)] 
 
6.3.4 Evaluating the Internalization of [23·MWCNTc(RGDfK)] via 
Confocal Studies 
 
In order to show that [23·MWCNTc(RGDfK)] was internalized by cells before 
releasing the payload, Ishikawa cells was treated with [23·MWCNTc(RGDfK)] 
for 6 hours before fixing and staining with Hoeschst 33342 nuclear dye. 
Although 23 was fluorescent by virtue of its Doxo motif, 
[23·MWCNTc(RGDfK)] did not exhibit fluorescence because it was obscured 
by its MWCNT carrier. This was shown by adding [23·MWCNTc(RGDfK)] 
onto untreated cells that had been fixed/stained before imaging (Figure 
37d). Upon internalization and cellular reduction, Doxo was released into 
the cytoplasm resulting in characteristic fluorescence at Ex = 488 nm: Em 




= 603 nm (Figure 37c). We observed that the Doxo released was distributed 
throughout the cytoplasm as well as the nucleus. In contrast, cells treated 
with Doxo were only localized within the nucleus (Figure 37b). Our 
hypothesis was that reduction of 23 yielded Doxo that was still conjugated 
to the succinate linker which imparted a negative charge to the conjugated 
entity instead of the free Doxo. This could delay the translocation of Doxo 
into the nucleus, leading to an altered distribution profile. 
      
Figure 37. Merged fluorescence image of Ishikawa cells (a) untreated 
(control), and exposed to (b) Doxo, (c) [23·MWCNTc(RGDfK)] (d) 
[23·MWCNTc(RGDfK)] added to fixed/stained untreated cells as background control 
 




6.3.5 Investigating the Reduction of Asymmetric Platinum(IV) Bis-
Carboxylate 23 
 
To validate our hypothesis that complex 23 went through cellular reduction to 
yield Doxo-succinate conjugate resulting in a lower anti-proliferative profile, 23 
was added to 3 mM ascorbic acid and monitored by RP-HPLC (500). The 
retention time of 23 was observed at 15.2 min on the HPLC chromatogram. Upon 
mixing with 3 mM ascorbic acid, a new peak with a retention time at 10.2 min 
appeared after 1 hour (Figure 38). ESI/MS analysis of the peak corresponding to 
retention time at 10.2 min showed the parent ion peak with m/z of 666 in the 
positive mode and 642 in the negative mode. These peaks corresponded to the 
[Doxo-succinate + Na]
+
 and [Doxo-succinate – H]- respectively. The presence of 
the free carboxylic acid group would lead to the formation of a charged species 
upon dissociation of the acidic carboxylic proton and be repelled from the 
hydrophobic cellular membrane leading to lower efficacy, as observed previously 
for complexes 4 and 5 (Chapter 4, Table 2). To overcome this, a platinum(IV)-
Doxo conjugate prodrug with a new linker that could allow the indiscriminate 
formation of free Doxo upon reduction could be designed and would be the 
subject of a new investigation. 




             
Figure 38. RP-HPLC Chromatograms depicting the reduction of complex 23 in 3 




With the goal of delivering drug combinations in exact ratiometric 
proportions against targeted cancers, a nanodelivery platform that releases 
cisplatin and a Doxo-derivate when internalized in cancer cells has been 
developed. To accomplish this, we design a water-dispersible non-cytotoxic 
MWCNT-based drug delivery platform that is surface-functionalized with 
integrin-targeting peptide groups. We also develope a hydrophobic 
asymmetric platinum(IV) bis-carboxylate, based on the cisplatin template 
and conjugated to Doxo, that can be stably entrapped within the MWCNT 
interior cavity. To release the drug entities, we exploit the intracellular 
reductive environment to activate the platinum(IV) scaffold. Because the 
reduced product cisplatin and Doxo-derivate are intrinsically hydrophilic, 




they are efficiently released from MWCNT platform. We have also 
demonstrated that controlled drug release can be triggered under reducing 
conditions particularly after the constructs are taken up in cells. These drug-
loaded nano-constructs are also highly efficacious in vitro especially against 
endometrial adenocarcinoma cells. This strategy paves the way for the 
development of combination therapy regimens with precise molecular 
formulations at the target site for enhanced therapeutic effects.  
 
6.5 Experimental Procedures 
 
Unless otherwise noted, all procedures were carried out without taking 
precautions to exclude air and moisture. All solvents and chemicals were used as 
received without further treatment. Platinum(IV) complex 22 was synthesized as 
described in Chapter 3. Doxorubicin was purchased from Merlin Chemicals Ltd. 
c(RGDfK) peptide was purchased from ChinaPeptides Co. Ltd. RPMI 1640 
medium was purchased from Invitrogen (Carlsbad, CA, USA). 2,2’-
(Ethylenedioxy)diethylamine and dextran-coated charcoal were obtained from 
Sigma Aldrich. Penicillin, streptomycin and thiazolyl blue tetrazolium bromide 
(MTT) wereall obtained from Sigma Chemical Co (St. Louis, MO, USA). Fetal 
bovine serum (FBS) was from Hyclone (Thermo Scientific Inc., Logan, UT, 
USA). DMEM nutrient mix F12 and antibiotic-antimycotic were obtained from 
Life Technologies. The water used was of Milli-Q grade purified by a Milli-Q UV 
Purification System (Sartorius Stedim Biotech S.A., Aubagne Cedex, France). All 




other solvents and chemicals were of analytical grade or HPLC grade obtained 




H NMR spectra were recorded on a Bruker AMX 500 
spectrometer and the chemical shifts () were internally referenced by the residual 
solvent signals relative to tetramethylsilane. Mass spectra were measured using a 
Finnigan MAT LCQ ion trap ESI mass spectrometer. UV spectra were recorded 
on a Shimadzu UV-1800 UV spectrophotometer using 1 cm path-length quartz 
cuvettes. Platinum concentration determination was performed using Inductively-
Coupled Plasma Optical Emission Spectroscopy (ICP-OES) by CMMAC, NUS. 
Elemental analyses of selected platinum compounds were carried out on the 
Perkin-Elmer PE 2400 elemental analyzer by CMMAC, NUS. 
 
Synthesis of Complex 23. Compound 22 (20 mg, 37.2 µmol) and Doxo·HCl (30 
mg, 51.7 µmol) were stirred at r.t. in dried DMSO (5 mL) for 24 h. HBTU (21 
mg, 55.8 µmol) was also added to the solution mixture followed by catalytic 
amounts of triethylamine. The crude solution mixture was concentrate to 2 mL 
and precipitated by adding to excess water (20 mL). The residue was washed with 
water (3x5 mL) and acetone (3x5 mL). The residue was re-dissolved in DMF (2 
mL) and re-precipitated by adding to excess diethyl ether (20 mL). The precipitate 
was washed with diethyl ether (3x5 mL), dried in vacuo, to yield 23 as a dark red 
product. Yield: 27 mg (68%). 
1
H NMR (500 MHz, DMSO-d6):  7.85 (br, 3 H, 
Ar-H), 7.61 (d, 2H, Ar-H), 7.50 (d, 1H, Ar-H), 7.40 (t, 2H, Ar-H), 6.59 (br, 6 H, 




NH3), 5.43 (s, 1H, OCHO), 5.21 (s, 1H),  4.91 (s, 1H), 4.87 (t, 1H, CHCH3),  4.74 
(d, 1H),  4.58 (d, 2H, CH2OH), 4.17 (d, 1H), 3.96 (s, 3H, OCH3; s, 1H), 2.99 (m, 
2 H, CH2) 2.43 (t, 2H, CH2), 2.28 (t, 2H, CH2),  2.20 (d, 1 H), 2.09 (d, 1H), 1.85 
(d, 1H), 1.42 (d, 1H), 1.12 (d, 3H, CH3). ESI-MS (-ve mode): m/z = 1061.99 [M-
H]
-
. Anal. Calcd.: C, 42.91; H, 4.07; N, 3.95. Found: C, 42.95; H, 4.20; N, 3.78. 
 
Preparation of MWCNTTEG. Pristine MWCNTs were oxidised and purified as 
described in previous reported procedure.
194
 As-prepared MWCNToxidized (9.7 mg) 
were dispersed in DMF and sonicated for 5 min. TEG (111 μmol), NHS (45 
μmol), EDC·HCl (112 μmol), and DIPEA (112 μmol) were added in the 
suspension. The mixture was heated at 60 °C for 24 h and filtered through a 
hydrophilic PTFE membrane (MWCO 0.22 μm). The residue was washed with 
DMF and deionized water, and dried in vacuo to yield MWCNTTEG. The degree 
of amino-functionalization per gram of MWCNTTEG (amino-loading) was 
calculated through quantitative Kaiser Test.
195
 As-prepared MWCNTTEG (ca. 100 
μg) was incubated with 75 μL of 4 g/mL phenol in EtOH, 100 μL of 0.02 mM 
KCN in pyridine, and 75 μL of ninhydrin in EtOH at 100°C for 7 min. After 
heating, the reaction was diluted with 60% EtOH to 5 mL, and the UV absorbance 
at 570 nm. The amount of –NH2 groups (μmol/g in MWCNTamine) was calculated 
using the following equation: 
Amino amount (μmol/g) =








where A570 nm is the absorbance at the wavelength 570 nm; W is the weight of 
analysed nanotube sample (mg). Using this protocol, MWCNTTEG was 
ascertained to contain 680 μmol of NH2 groups/g MWCNTTEG. 
 
Preparation of MWCNTTEG-COOH. MWCNTTEG (10.0 mg) were dispersed in 
DMSO (3 mL) under sonication (5 min). Succinic anhydride (1.0 g) was then 
added to the suspension and the reaction mixture was allowed to stir at r.t. for 3 d. 
The reaction mixture was filtered, washed with DMSO (3 x 5 mL) and dialysed in 
water for 24 h to remove any unreacted succinic anhydride. Quantitative Kaiser 
Test (see preparation of MWCNTTEG) on MWCNTTEG-COOH yielded a negative 
result indicating complete reaction of the amine groups.  
 
Preparation of MWCNTc(RGDfK). MWCNTTEG-COOH (5.0 mg) were dispersed in 
dried DMF (3 mL) under sonication (5 min). c(RGDfk) (30.0 mg, 50 μmol) was 
then added to the suspension followed by the addition of HBTU (19.0 mg, 50 
μmol) and catalytic amounts of triethylamine. The reaction mixture was allowed 
to stir for 2 d at r.t., filtered, and washed with DMF (3 x 5 mL). The residue was 
then washed with diethyl ether (3 x 5 mL) and dried in vacuo. Final weight of the 
MWCNTc(RGDfK) synthesized was found to be 7.7 mg. 
 
Entrapment of Doxo in MWCNTTEG [Doxo·MWCNTTEG]. 4.5 mg of Doxo 
and 2.2 mg of MWCNTTEG were mixed in 1.5 mL of CHCl3 under a brief 
sonication. The mixture was stirred at room temperature for 5 d, filtered through 
PTFE membrane, and washed with deionized H2O to remove unbound Doxo. The 




product was recovered from PTFE membrane by dissolving in diethyl ether, and 
the suspension was centrifuged to discard the supernatant. The precipitating 
product MWCNTTEG-DOX was dried in vacuo and found to be 2.9 mg. However, 
the exact loading of [Doxo·MWCNTTEG] could not be determined due to possible 
loss of materials through washing and presence of solvent molecules. 
 
Entrapment of 23 in MWCNTTEG [23·MWCNTTEG]. Complex 23 (5.0 mg) and 
MWCNTTEG (1.9 mg) were suspended in H2O (1.5 mL) under a brief sonication. 
The mixture was stirred at r.t. for 5 d, filtered through PTFE membrane, washed 
with CHCl3:MeOH:H2O (2:2.5:1 v/v). The product formed [23·MWCNTTEG] was 
dried in vacuo. The Pt content was ascertained to be 24.3 ± 0.8% w/w as analysed 
using TGA and ICP-OES. 
 
Entrapment of 23 in MWCNTc(RGDfK) [23·MWCNTc(RGDfK)]. Complex 23 (3.0 
mg) and MWCNTTEG (2.0 mg) were suspended in H2O (1.5 mL) under a brief 
sonication. The mixture was stirred at r.t. for 5 d, filtered through PTFE 
membrane, washed with CHCl3:MeOH:H2O (2:2.5:1 v/v). The product formed 
[23·MWCNTc(RGDfK)] was dried in vacuo. The Pt content was ascertained to be 
24.5 ± 1.0% w/w as analysed using TGA and ICP-OES. 
 
Quantification of entrapped platinum complexes by TGA and ICP-OES. The 
samples were heat in air at a heating rate of 10°C/min until a final temperature of 




1000°C was reached. The remaining residue was dissolved in aqua regia and 
diluted with 2% HNO3 for ICP-OES determination of Pt levels. 
 
Doxo Release Experiment. [Doxo·MWCNTTEG] (< 0.1 mg) was suspended in 
deionized H2O (150 L), transferred to a dialysis button, and immersed in 
deionized H2O (10 mL) to evaluate its stability in H2O. [23·MWCNTTEG] (1.5 
mg) was suspended in deionized H2O (300 L), transferred equally to two release 
buttons (150 L each), followed by immersion in 10 deionized H2O (10 mL) and 
aq. ascorbic acid solution (3 mM, 10 mL), separately. For each experiment, the 
dialysis media was replaced at 20 min, 40 min, 1 h, 2 h, 4 h, 6 h, 9 h, 12 h, 24 h, 
48 h, 72 h, 96 h after the immersion and their UV absorbance determined at 500 
nm (corresponding to Doxo max). Because loading of [Doxo·MWCNTTEG] could 
not be determined, the time-point at 96 h was approximated as terminal release. 
  
Tissue Culture. A2780 and A2780/Cis were cultured in complete RPMI 1640 
medium containing 100 units/mL penicillin, 100 g/mL streptomycin and 10% 
fetal bovine serum (FBS). In order to maintain resistance, 1 µM cisplatin need to 
be added to the media for A2780/Cis every 2-3 passages. The endometrial 
carcinoma cells Ishikawa (ATCC) was cultured in complete DMEM F12 medium 
containing 10% FBS pretreated with dextran coated charcoal and 1% antimycotic 
(100x). The three cell lines were grown at 37
o
C in a humidified atmosphere of 
95% air and 5% CO2. Experiments were performed on cells within 20 passages. 
Viable cells were counted using the Trypan Blue exclusion method. 





Inhibition of cell viability assay. Drug effects on exponentially growing tumor 
cells were determined using MTT assay as described in Chapter 4. A2780, 
A2780/Cis and Ishikawa cells were seeded at a density of 6,000 cells per well in 
96-well plates and incubated for 24 h. Cells were exposed to compounds at 
different concentrations in their respective medium without FBS and antibiotics. 
These compounds were prepared as DMSO stock solutions and serially diluted 
with DMSO to a series of decreasing concentrations, before diluting to the 
required concentrations in culture media. In this manner, all cells were exposed to 
1% v/v DMSO, at which negligible cytotoxicity were observed. The cells were 
incubated with the test compounds for 6 h, replaced with fresh compound-free 
complete medium (with FBS and antibiotics) and incubated for 66 h. After 72 h 
following compound administration, the medium was aspirated, replaced with 
MTT assay solution (100 µL, 0.5 mg/mL in PBS) and incubated for a further 4 h 
at 37°C. The medium was aspirated and the purple formazan precipitate dissolved 
in DMSO (100 µL). Absorbance was measured at a 570 nm using a microplate 
reader (BioTek). Experiments were performed in triplicates for each concentration 
and carried out independently at least three times. Cytotoxicity was evaluated 
with reference to the IC50 value which was defined as the concentration needed 
for a 50% reduction of survival based on the survival curves. IC50 values were 
calculated from dose-response curves (cell survival vs. drug concentration) 
obtained in repeated experiments and adjusted to actual [Pt] administered which 
was separately determined using ICP-OES. 





Pt uptake in Ishikawa cells. Ishikawa carcinoma cells were cultured DMEM F12 
medium supplemented with 10% FBS and 1% antibiotics. Two samples were 
prepared namely, [23·MWCNTc(RGDfK)] and 23, both of which are adjusted to 33.0 
µM [Pt] concentrations determined from ICP-OES.  Ishikawa cells were seeded in 
30 mm cell culture dishes at a density of 3.5×10
6
 cells per dish and the dishes 
were incubated at 37°C with 5% CO2 for 48 h prior to treatment with the samples. 
Cells were exposed to [23·MWCNTc(RGDfK)] or 23 in serum-free media for 3 h and 
replaced with fresh complete media for a further 3 h incubation. Control plates 
were also carried out during which cells were exposed to serum-free media 
without addition of the test compounds. After 6 h of incubation, the dishes were 
placed on ice and cell monolayer was washed with ice-cold PBS (2x5 mL). PBS 
(1 mL) was added to each dish, and cells were collected with a scraper and 
counted. The cells were pelleted by centrifugation for 15 min at 4°C. 
Concentrated HNO3 (65% v/v, 150 µL) was added to the cells in an uncapped 
sample vial and heated at 90
o
C overnight to digest the cells. The digested solution 
was diluted with MilliQ water (3 mL) prior to ICP-MS analysis. 
 
Cell culture experiment for confocal studies. Ishikawa cells were cultured in 
MEM medium supplemented with 2 mM glutamine, 1% non-essential amino 
acids (NEAA) and 5% FBS at 37°C with 5% CO2. Cells were seeded on cover 
slip in 6-well plates at a density of 12 x 10
4 
cells per mL and incubated 12 h 
before treatment. During treatment, the medium was replaced with incubation 




media containing either blank MWCNTc(RGDfK), (b) Doxo·HCl, (c) 23, (d) 
[23·MWCNTc(RGDfK)] (3 μM [Pt]) in MEM at 37°C with 5% CO2 for 6 h, as well 
as untreated controls. After 6 h incubation, the cells were washed twice with PBS, 
fixed with 4% paraformaldehyde for 15 min, stained with Hoechst 33342 nuclear 
stain (1.3 μg/mL) and then washed twice with PBS. 
 
Identification of the Doxo-derivative upon reduction of 23. Complex 23 was 
dissolved in 1% DMSO of 3 mM ascorbic acid in 2 mL microtubes, centrifuged 
and analyzed. The reduction was monitored using analytical HPLC on a 
Shimadzu Prominence using an Agilent ZORBAX Eclipse Plus column (5 μm, 
120 Å, 4.60 x 150 mm, 1.0 mL min
-1
 flow) with UV detection at 500 nm. The 
isocratic eluent conditions were as follows: 60% water and 40% MeCN for 25 
mins. The peak corresponding to the Doxo-derivative was collected using fraction 






The strategies that have been presented in this dissertation represent a novel 
methodical approach in rational drug design and development to overcome the 
current limitations of classical symmetric platinum(IV) bis-carboxylates and FDA 
approved anticancer drug, cisplatin. Using a non-classical synthetic approach, 
asymmetric platinum(IV) bis-carboxylates bearing cisplatin pharmacophores were 
constructed via sequential carboxylation with the aim of being able to fine-tune 
the overall properties of the prodrugs by varying the ligands in the axial positions. 
Reduction of this novel class of compounds will result in the concomitant 
dissociation of the axial ligands leading to the formation of cisplatin. Most of the 
synthesized compounds represent “proof-of-concepts” based on specific design 
hypotheses. 
 
The classical symmetric platinum(IV) bis-carboxylates are unable to exhibit good 
aqueous solubility and lipophilicity simultaneously, which undermine their 
clinical applications. The development of asymmetric platinum(IV) bis-
carboxylates by introducing both lipophilic and hydrophilic ligands in the axial 
positions resulted in lipophilic prodrugs that are soluble in aqueous media and 
also exhibited cytotoxicity comparable to cisplatin against human ovarian 
carcinoma cell lines. Extensive studies on the series of finely-tuned asymmetric 
platinum(IV) complexes show an inter-properties dependency that affect the
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 overall efficacies of the prodrugs. These properties include lipophilicity, 
reduction rate, and cytotoxicity. Understanding these correlations will allow a 
more effective design and development of platinum(IV) prodrugs suitable for 
clinical evaluation. Based on our investigations, asymmetric platinum(IV) bis-
carboxylate 7 has been selected for further in-depth analysis that include in vivo 
and pharmacokinetic studies due to its good aqueous solubility, lipophilicity, and 
anti-proliferative properties. In addition, we have also shown that the 
photoactivatable properties of platinum(IV) complexes can also be fine-tuned by 
constructing asymmetric platinum(IV) bis-carboxylates with varying axial ligands 
to achieve the desired λmax. This represents a strategy of utilizing asymmetric 
platinum(IV) bis-carboxylate framework to customize anticancer prodrugs with 
engineered properties. 
 
Other than small organic molecules, it is also possible to conjugate biomolecule in 
the axial position of platinum(IV) complexes for co-delivery of drugs to achieve 
synergism in a multi-functional approach. Through asymmetric carboxylation, we 
have successfully developed a platinum(IV) prodrug, 23,  which consists of exact 
equivalent of cisplatin and doxorubicin. The other axial ligand serves as a handle 
to fine-tune the overall property of the compound such as stability
84
 and in our 
example, lipophilicity. The improve lipophilicity of 23 allows favorable 
entrapment into tumor-targeting MWCNT as delivery platform via hydrophobic-
hydrophobic interaction. This increases the potency of 23 against a range of 
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human carcinoma cell lines, in particular the endometrial adenocarcinoma cells, 
due to increased drug accumulation arising from a more targeted perspective. 
7.1 Future Prospect of Platinum-Based Anticancer Drugs  
 
Since the discovery of cisplatin, more than 10,000 platinum-based complexes 
have been developed but only 3 of them have obtained FDA-approval. They are 
cisplatin, carboplatin and oxaliplatin. This extremely low success ratio has fueled 
concerns over the prospect of platinum-based anticancer agents in the future, 
especially now that the more renowned platinum-based researchers have slowly 
shifted their focus to ruthenium-, rhodium- and even osmium-based anticancer 
agents. In addition, the overly reliance on in vitro model to evaluate the efficacies 
of these novel platinum-based agents with different pharmacophores and DNA-
binding affinities reveal little about their mechanisms and does not give accurate 
and convincing analysis prior to clinical evaluations, resulting in a lack of 
progress for platinum-based complexes. The search for novel methodologies, 
chemistry and drug designs to create a niche for oneself in this academic driven 
field has often neglected existing ones that could be useful in rational drug design 
against cancers and compromised progress, resulting in a lack of clinical 
applications.  
 
Moving forward, it is likely we will, or have already, seen a shift of research 
focus from platinum(II) to platinum(IV) based anticancer complexes. Prodrugs of 
cisplatin have undergone intensive studies to improve its efficacies, overcome its 
limitations and even increase its functionalities. Given the well-studied and 
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established advantages of platinum(IV) prodrugs over their platinum(II) 
counterparts, the next FDA-approved platinum-based anti-cancer agent may 
potentially be a platinum(IV) prodrug of cisplatin other than satraplatin, which is 
still undergoing various clinical evaluations.  
 
In the near future, there could be an increased interest in developing platinum(IV) 
prodrugs of carboplatin and oxaliplatin, the other two platinum-based FDA 
approved anticancer drugs. This is especially so for oxaliplatin, which has been 
recently found to give rise to immunogenic cell deaths, a process whereby cell 
death leads to the release of damage-associated molecular pattern molecules and 
triggers the immune system.
196
 The ability to fine-tune the pharmacological 
properties of oxaliplatin prodrugs to further enhance anti-proliferative efficacies 
against tumor cells would certainly be beneficial for future clinical applications. 
 
Today, the development of platinum-based anticancer drugs stands at a crossroad. 
The limitations and inadequacies of platinum(II)-based anti-cancer drugs and 
classical drug development of symmetric platinum(IV) prodrugs are clear, while 
the non-classical approach in the development of symmetric platinum(IV) 
complexes is still at its infancy stage. Nonetheless, given the strong interest in this 
area, advancement in scientific knowledge and analytical tools and an ever 
increasing cancer population, we are likely to witness greater development in 
platinum-based anticancer drugs. Whether we see the development of a new class 
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Table 7. Selected X-ray crystallographic data for A and 3 
Complex (Compound A)
.





Formula weight 516.3 1018.50 
Temperature [K] 100(2) 293(2) 
Wavelength [Å] 0.71073 0.71073 
Crystal size [mm3] 0.33 × 0.24 × 0.18 0.50 x 0.14 x 0.08 
Crystal system monoclinic monoclinic 
Space group C2/m P21/c 
a [Å] 17.064(3) 13.660(3) 
b [Å] 7.2554(12) 9.867(2) 
c [Å] 12.642(2) 23.937(6) 
α [deg] 90 90 
β [deg] 102.211(3) 98.520(5) 
γ [deg] 90 90 
V [Å3] 1529.8(4) 3190.6(13) 
Z 4 8 
Dc [Mg/m
3] 2.242 2.120 
μ [mm-1] 9.667 9.145 
θ range [deg] 2.44 − 27.45 2.11 to 27.50 
no. of unique data 5357 22207 
max., min. transmn 0.2750 and 0.1426 0.5282 and 0.0918 
final R indices R1 = 0.0261 R1 = 0.0427 
[I>2σ(I)] wR2 = 0.0711 wR2 = 0.0953 
R indices (all data) R1 = 0.0273 R1 = 0.0514 




peak/hole [e Å-3] 2.070 and -0.922 4.522 and -1.310 
aR = Σ||Fo| − |Fc||/Σ|Fo|, wR2 = {Σ[w(Fo2 − Fc2)2]/Σ[w(Fo2)2]}1/2. Goodness-of-fit (GOF) = 
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